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Context and Significance {#sec1}
========================

**Astrocytes represent central regulators of brain glucose metabolism and neuronal function. In this study, researchers at** **Max Planck Institute** **and their collaborators discovered that astrocytes within different brain regions express the receptor for GLP-1, a hormone known to regulate systemic glycemia and food intake. They uncovered that GLP-1 inhibits glucose uptake and promotes the utilization of fatty acids in astrocytes and demonstrated a role for astrocyte GLP-1R signaling in maintaining mitochondrial integrity. Lack of GLP-1R signaling in astrocytes mounts an adaptive stress response resulting in an improvement of systemic glucose homeostasis and memory formation. These results reveal a novel role for GLP-1 in controlling fuel utilization in astrocytes, a process with potential implications for the regulation of neuronal function and neurodegeneration.**

Introduction {#sec2}
============

Extensive research over the last decades uncovered distinct neuronal populations within the hypothalamus as master regulators of systemic energy metabolism, integrating information about the nutritional status of the organism into a coordinated feedback response on food intake, glucose homeostasis, and energy expenditure ([@bib95]). However, recent studies unraveled that astrocytes, the most abundant cell type in the adult brain ([@bib23]), play a major role in the central control of glucose and energy metabolism ([@bib25], [@bib26], [@bib41], [@bib100], [@bib105], [@bib107]). Here, astrocytes not only regulate systemic glucose and energy homeostasis in response to leptin ([@bib41]) and insulin ([@bib26]) but also modulate brain metabolism via control of glucose transport ([@bib26]) to adapt behavioral responses ([@bib100]).

Interestingly, astrocytes also express the glucagon-like peptide (GLP)-1 receptor (GLP-1R) ([@bib3], [@bib13], [@bib106]). GLP-1, derived from the *proglucagon* gene, has originally been identified as an incretin hormone released from enteroendocrine L-cells upon nutrient ingestion. In pancreatic islets, GLP-1 promotes glucose-dependent insulin secretion while inhibiting glucagon release, making it an attractive target for the treatment of type 2 diabetes mellitus ([@bib19]). As circulating endogenous GLP-1 has a half-life of only several minutes ([@bib32]), multiple long-acting GLP-1R agonists have been developed, which are widely used for the treatment of type 2 diabetes mellitus ([@bib19], [@bib42]). In addition to their glucoregulatory effects, GLP-1R agonists promote satiety and reduce food intake both in rodents and humans ([@bib19]) and thus entered clinical routine for the treatment of obesity. Furthermore, numerous preclinical studies point toward a broad neuroprotective effect of GLP-1R agonists in rodent models ([@bib106]) with already promising therapeutic efficacy in recent clinical trials in patients with Parkinson's ([@bib5], [@bib6]) and Alzheimer's disease ([@bib27]).

Importantly, GLP-1 is also produced by distinct *proglucagon*-expressing neurons in the nucleus of the solitary tract (NTS) of the hindbrain, which project to various brain regions, including the hypothalamus ([@bib90]). Within the central nervous system (CNS), endogenous GLP-1 acts as a modulator of food intake and body weight as revealed by hypothalamus-specific deletion of the GLP-1R ([@bib54], [@bib55]). Recent work has highlighted the marked differences between action of endogenous GLP-1 and effects of exogenously applied GLP-1R agonists: while systemically administered GLP-1R agonists induce weight loss in the absence of GLP-1R expression in the paraventricular nucleus of the hypothalamus (PVH) ([@bib10], [@bib90]), the anorexigenic effects of endogenous GLP-1 were abolished upon PVH-specific GLP-1R deletion ([@bib54]). Overall, the exact cellular target(s) mediating the neuronal metabolic effects of central GLP-1 and GLP-1R agonists remain to be fully elucidated. More recently, it was shown that the anorexia-inducing effect of a GLP-1R agonist in the hindbrain is, at least in part, mediated via astrocytes ([@bib75]). Given the emerging importance of astrocytes in central energy metabolism control, we aimed at investigating the role of endogenous GLP-1R signaling in astrocytes in the regulation of brain and systemic energy and glucose homeostasis.

Results {#sec3}
=======

GLP-1 Promotes β-Oxidation in Cultured Hypothalamic Astrocytes {#sec3.1}
--------------------------------------------------------------

In an attempt to investigate the potential role of GLP-1 action in astrocytes, we first assessed the expression of the GLP-1R in astrocytes via RNAscope-based *in situ* hybridization as well as via assessment of uptake of the fluorescently labeled GLP-1R agonist liraglutide (liraglutide^594^) in distinct brain areas in C57Bl6/N control mice as well as in mice lacking the GLP-1R (GLP-1R^Δ/Δ^ mice) ([@bib89]). This analysis revealed astrocyte GLP-1R expression in the arcuate nucleus of the hypothalamus (ARH), the PVH, the hippocampus, and the NTS in control mice, but not in GLP-1R^Δ/Δ^ mice ([Figures S1](#mmc1){ref-type="supplementary-material"}A and S1B), while there was no astrocyte GLP-1R expression detectable in the nucleus accumbens (Acc) in control and GLP-1R^Δ/Δ^ mice ([Figures S1](#mmc1){ref-type="supplementary-material"}A and S1B).

Having validated the expression of the GLP1-R in astrocytes, we studied the effects of GLP-1R activation in cultured hypothalamic astrocytes. Here, we assessed alterations of *GLP-1R* expression in primary astrocytes isolated from C57Bl6/N wild-type mice upon incubation at 25 or 2 mM glucose, revealing increased *GLP-1R* expression in astrocytes under low- versus high-glucose conditions ([Figure S2](#mmc1){ref-type="supplementary-material"}A).

We next investigated if GLP-1 treatment potentially alters glucose uptake in primary hypothalamic astrocytes. Treatment of glucose-starved hypothalamic astrocytes with 100 nM GLP-1 for 30 min led to a reduction in subsequent glucose uptake ([Figure S2](#mmc1){ref-type="supplementary-material"}B). We then studied how the acute decrease in glucose uptake upon GLP-1 treatment impacts astrocyte cellular metabolism and mitochondrial respiration. To this end, we treated glucose-deprived primary astrocytes with 100 nM GLP-1 in the presence or absence of etomoxir, an inhibitor of mitochondrial fatty acid uptake and thus subsequent oxidation ([@bib82], [@bib103]), and assessed mitochondrial respiration in the presence of glucose. While GLP-1 treatment affected neither basal nor maximal mitochondrial oxygen consumption rate (OCR) or ATP production in the absence of etomoxir, mitochondrial oxidative phosphorylation (OXPHOS) was reduced upon GLP-1 treatment when fatty acid oxidation was inhibited by etomoxir ([Figures S2](#mmc1){ref-type="supplementary-material"}C and S2D). Of note, etomoxir alone did not alter astrocyte mitochondrial respiration in the presence of glucose ([Figures S2](#mmc1){ref-type="supplementary-material"}C and S2D). The observation that mitochondrial respiration was impaired upon GLP-1 in the presence, but not in the absence, of etomoxir led us to hypothesize that GLP-1 might induce fatty acid oxidation at the expense of reduced glucose utilization. Therefore, we assessed astrocyte fatty acid oxidation in glucose-deprived primary hypothalamic astrocytes upon acute GLP-1 treatment. Indeed, exogenous fatty acid oxidation in the presence of palmitate ([Figures S2](#mmc1){ref-type="supplementary-material"}E and S2F) and endogenous fatty acid oxidation in the presence of BSA ([Figures S2](#mmc1){ref-type="supplementary-material"}G and S2H) were enhanced upon acute GLP-1 treatment.

Next, we aimed to determine whether the observed effects of GLP-1 depended on astrocyte-autonomous GLP-1R signaling. To this end, primary astrocytes from the hypothalamus of 1- to 3-day-old GLP-1R^flox/flox^ pups were isolated and cultured as previously described ([@bib26]) ([Figure S3](#mmc1){ref-type="supplementary-material"}A). GLP-1R deletion in primary hypothalamic astrocytes was induced by incubating cells with an AAV expressing either Cre or GFP as a control ([@bib26]), resulting in successful reduction of GLP-1R protein ([Figure S3](#mmc1){ref-type="supplementary-material"}B) and mRNA ([Figure S3](#mmc1){ref-type="supplementary-material"}C) expression upon Cre-mediated deletion. Comparing control and GLP-1R-deficient astrocytes showed that the effects of GLP-1 on mitochondrial fatty acid oxidation were impaired in GLP-1R-deficient ([Figures S3](#mmc1){ref-type="supplementary-material"}E and S3F) compared to control astrocytes ([Figures S3](#mmc1){ref-type="supplementary-material"}D and S3F).

GLP-1R Ablation in Hypothalamic Astrocytes Impairs Mitochondrial Function {#sec3.2}
-------------------------------------------------------------------------

Given the critical role of mitochondria in substrate utilization of astrocytes, we decided to investigate the dependence of cultured hypothalamic astrocytes on functional endogenous GLP-1R expression. Here, we compared mitochondrial respiration in control and GLP-1R-deficient hypothalamic astrocytes. Real-time measurement of mitochondrial OCR revealed a slight impairment in basal and maximal mitochondrial respiration as well as in mitochondrial ATP production in hypothalamic astrocytes upon GLP-1R deletion ([Figures 1](#fig1){ref-type="fig"}A and 1B). We therefore analyzed the protein expression of subunits of mitochondrial respiratory chain complexes in these cells. GLP-1R deletion was associated with a slight reduction in protein expression of the complex I subunit NDUFB8, while other mitochondrial complexes, including the complex I subunit NDUFA9, were not altered ([Figures 1](#fig1){ref-type="fig"}C and 1D). Of note, mitochondrial mass was not changed in primary astrocytes upon GLP-1R deletion ([Figure 1](#fig1){ref-type="fig"}E). NDUFB8 deficiency results in mitochondrial complex I dysfunction ([@bib70]). As complex I dysfunction is associated with compensatory increased glucose uptake ([@bib52]), we next investigated if GLR-1R deletion affects glucose handling in primary hypothalamic astrocytes *ex vivo*. Indeed, glucose uptake was enhanced in primary hypothalamic astrocytes with GLP-1R deficiency compared to control astrocytes ([Figure 1](#fig1){ref-type="fig"}F). Glucose uptake in astrocytes is mainly mediated via glucose transporter (GLUT)-1 ([@bib26], [@bib91]). Therefore, we investigated if the increase in glucose uptake upon GLP-1R ablation in primary astrocytes might involve altered GLUT-1 regulation. Glucose-starved GLP-1R-deficient astrocytes showed increased levels of phosphorylated Ser-226 on GLUT-1 ([Figure 1](#fig1){ref-type="fig"}G), which has been shown to enhance GLUT-1-mediated glucose uptake ([@bib48]). In line, enhanced glucose uptake in GLP-1R-deficient astrocytes was prevented upon pre-incubation with the GLUT-1 inhibitor WBZ117 ([Figure 1](#fig1){ref-type="fig"}H).Figure 1GLP-1R Ablation in Hypothalamic Astrocytes Alters Mitochondrial Function Associated with Increased Glucose Uptake and Glycolytic Flux(A and B) Representative analysis (A) and quantification (B) of baseline oxygen consumption rate (OCR) before (no gluc) and after glucose (with gluc) administration. ATP-linked and maximum respiration OCR in GLP-1R-deficient (GLP-1R KO) and control hypothalamic astrocytes (representative experiment from n = 8 independently isolated astrocyte cultures).(C and D) Western blot analysis (C) and quantification of expression (D) of respiratory chain subunits in GLP-1R KO and control hypothalamic astrocytes (n = 4 independently isolated astrocyte cultures).(E) Mitochondrial content in GLP-1R KO and control hypothalamic astrocytes (ratio of mitochondrial DNA to nuclear DNA \[mtDNA/nDNA\]) (n = 3 independently isolated astrocyte cultures).(F) Glucose uptake in GLP-1R KO and control hypothalamic astrocytes (n = 9 independently isolated astrocyte cultures).(G) Representative immunoblots of Ser-226 GLUT-1 phosphorylation in GLP-1R KO and control hypothalamic astrocytes. Quantification of pSer226-GLUT1 levels was performed after normalization to total GLUT1 and calnexin as loading control (n = 12 independently isolated astrocyte cultures).(H) Glucose uptake in the presence or absence of the GLUT-1 inhibitor WBZ117 in GLP-1R KO and control hypothalamic astrocytes (n = 6 independently isolated astrocyte cultures).(I) Representative glycolytic flux analysis in GLP-1R KO and control hypothalamic astrocytes upon incubation with 2 or 25 mM glucose.(J) Log2-transfomed proportional values and quantification of glycolytic capacity normalized to control 2 mM glucose as described in (I) from n = 4 independently isolated astrocyte cultures.(K--P) Cellular glycolytic metabolites in GLP-1R KO and control hypothalamic astrocytes upon administration of 2 or 25 mM glucose for 1 h (n = 5 independently isolated astrocyte cultures).(Q) Lactate secretion of GLP-1R KO and control hypothalamic astrocytes upon administration of 2 or 25 mM glucose for 1 h (n = 15 independently isolated astrocyte cultures).Data are presented as mean ± SEM. ^∗^p ≤ 0.05, ^∗∗^p ≤ 0.01, ^∗∗∗^p ≤ 0.001 as determined by unpaired Mann-Whitney test (D), two-tailed Student's t test (B, F, and G), and two-way ANOVA followed by Bonferroni post hoc test (H and J--Q). See also [Figures S1--S4](#mmc1){ref-type="supplementary-material"}.

Next, we intended to elucidate how the increase in glucose uptake impacts cellular energy metabolism upon GLP-1R deletion in hypothalamic astrocytes. Exposure of primary hypothalamic astrocytes to low and high glucose concentrations revealed that glycolytic capacity, as measured by extracellular acidification rate (ECAR), was increased in GLP-1R-deficient astrocytes in the presence of both low and high glucose ([Figures 1](#fig1){ref-type="fig"}I and 1J), in line with an increased glucose uptake fueling aerobic glycolysis to apparently compensate for the slight reduction in OXPHOS ([@bib35], [@bib73], [@bib93]). Accordingly, metabolic profiling revealed reduced intracellular concentrations of glycolytic metabolites ([Figures 1](#fig1){ref-type="fig"}K--1P) but an unaltered lactate secretion of GLP-1R-deficient compared to control astrocytes ([Figure 1](#fig1){ref-type="fig"}Q), overall indicating a higher glycolytic flux in astrocytes lacking GLP-1R expression.

Mitochondria adapt to changes in energy state and nutrient supply by morphological changes such as fusion and fission ([@bib101]). Accordingly, acute systemic glucose loading induces changes in mitochondrial morphology in neurons ([@bib62]) and astrocytes ([@bib26]) within the ARH. To assess astrocyte mitochondrial dynamics upon glucose exposure *ex vivo*, GLP-1R-deficient and control hypothalamic astrocytes were incubated at low glucose concentrations and then exposed to either low or high glucose concentrations before assessing mitochondrial morphology via TOM20 immunostaining ([Figure 2](#fig2){ref-type="fig"}A). These experiments revealed that *ex vivo* acute glucose exposure induced mitochondrial elongation in glucose-deprived control astrocytes, while these changes in mitochondrial morphology were absent in astrocytes lacking GLP-1Rs ([Figure 2](#fig2){ref-type="fig"}B). In summary, GLP-1R deficiency alters mitochondrial adaptations to an acute glucose challenge in hypothalamic astrocyte *ex vivo*.Figure 2Reduction of GLP-1R Expression Alters Mitochondrial Integrity in Hypothalamic Astrocytes(A) Representative confocal images of immunocytochemistry detection of TOM20 (green) and nuclear counterstaining (DAPI, blue) in cultured GLP-1R-deficient (GLP-1R KO) and control primary hypothalamic mouse astrocytes in response to a 20 min incubation with low glucose (2 mM glucose) or high glucose (25 mM glucose) after incubation at 2 mM glucose. Scale bars, 50 μm.(B) Quantification of mitochondrial morphology in GLP-1R KO and control primary hypothalamic mouse astrocytes upon treatment conditions as described in (A) (n = 3 independently isolated astrocyte cultures).Data are presented as mean ± SEM. ^∗^p ≤ 0.05, ^∗∗^p ≤ 0.01 as determined by two-way ANOVA followed by Bonferroni post hoc test.

Mitochondrial dysfunction in general and in particular upon reduction of NDUFB8 expression is associated with the activation of an integrated stress response resulting in increased expression and release of FGF21 in various cell types ([@bib1], [@bib29], [@bib69], [@bib76]). Interestingly, FGF21 is also expressed in cultured glia cells ([@bib57]). Indeed, GLP-1R deficiency resulted in increased expression of *activating transcription factor* (*ATF*) *4*, a key regulator of the integrated stress response upon mitochondrial dysfunction ([@bib40]) ([Figure S4](#mmc1){ref-type="supplementary-material"}A). Regarding other ATF4-induced stress response genes, only *ATF5* was upregulated, while expression of *CHOP*, *Bip*, or *PPARα* was not altered in GLP-1R-deficient astrocytes ([Figure S4](#mmc1){ref-type="supplementary-material"}A). Moreover, *FGF21* expression was slightly increased in primary hypothalamic astrocytes upon GLP-1R ablation ([Figure S4](#mmc1){ref-type="supplementary-material"}B). In summary, GLP-1R deletion in primary astrocytes is associated with a mild impairment in mitochondrial function in the presence of reduced NDUFB8 expression, which promotes a compensatory increase in GLUT-1-mediated glucose uptake, aerobic glycolysis, and an increase in *FGF21* expression.

Generation of a Mouse Model with Inducible Astrocyte-Specific GLP-1R Deletion {#sec3.3}
-----------------------------------------------------------------------------

To study the role of GLP-1R signaling in astrocytes *in vivo*, we generated mice allowing for ablation of GLP-1R expression in astrocytes in a time-controlled manner in adult mice. To this end, we crossed mice expressing the tamoxifen-sensible fusion protein of a mutant ligand-binding domain of the estrogen receptor with the Cre recombinase (CreERT2) under the control of the human glial fibrillary acidic protein (hGFAP) promotor ([@bib24]) to mice carrying a loxP flanked human GLP-1R in the mouse GLP-1R locus ([@bib38]). Tamoxifen application allowed for postnatal deletion of the GLP-1R in GFAP-expressing astrocytes (GLP-1R^ΔGFAP^ mice). Functional GLP-1R expression in astrocytes in the ARH of control mice and GLP-1R deletion in GLP-1R^ΔGFAP^ mice were investigated upon intraperitoneal injection with fluorescently labeled liraglutide^594^ ([@bib90]) ([Figure 3](#fig3){ref-type="fig"}A). While uptake of liraglutide^594^ was detectable in GFAP-expressing astrocytes in the ARH of control mice, in GLP-1R^ΔGFAP^ mice liraglutide^594^ uptake was reduced in GFAP-expressing astrocytes ([Figure 3](#fig3){ref-type="fig"}A). Accordingly, the percentage of liraglutide^594^-positive GFAP astrocytes was reduced in GLP-1R^ΔGFAP^ compared to control mice ([Figure 3](#fig3){ref-type="fig"}B), while there was no difference in the number of all liraglutide^594^-labeled ([Figure 3](#fig3){ref-type="fig"}C) and liraglutide^594^-labeled, GFAP-negative ARH cells ([Figure 3](#fig3){ref-type="fig"}D) between the genotypes. Furthermore, numbers of GFAP-expressing astrocytes did not differ between GLP-1R^ΔGFAP^ and control mice ([Figure 3](#fig3){ref-type="fig"}E). These results further supported that the GLP-1R is expressed in hypothalamic astrocytes as well as successful Cre-dependent reduction of GLP-1R expression in GFAP-positive hypothalamic astrocytes in our mouse model *in vivo*.Figure 3Generation of a Mouse Model with Inducible Astrocyte-Specific GLP-1R DeletionRepresentative confocal images (A) and quantification (B--E) of immunohistochemistry detection of liraglutide^594^ uptake (red), GFAP (green), and corresponding nuclear counterstaining (DAPI, blue) in the arcuate nucleus of the hypothalamus (ARH) of GLP-1R^ΔGFAP^ and control mice (n = 4 mice per genotype). Filled arrows, liraglutide^594^-positive, GFAP-double-positive cells; dotted arrows, liraglutide^594^-positive, GFAP-negative cells; arrowheads, liraglutide^594^-negative, GFAP-positive cells. 3V, third ventricle, Scale bars, 100 μm. Data are presented as mean ± SEM of (B) the percentage of liraglutide^594^-positive, GFAP-positive astrocytes; (C) the average number of all liraglutide^594^-positive cells; (D) the average number of all liraglutide^594^-positive, GFAP-negative cells; and (E) all GFAP-positive cells per hemi-ARH. ^∗∗^p ≤ 0.01 as determined by two-tailed, unpaired Student's t test (B--E).

Deficient Astrocyte GLP-1R Signaling Improves Systemic Glucose Homeostasis {#sec3.4}
--------------------------------------------------------------------------

We then investigated whether mice with reduced GLP-1R expression in astrocytes display alterations in systemic glucose handling and energy homeostasis. To this end, we performed glucose tolerance tests, revealing an improved ability to clear a peripheral glucose load in mice with astrocyte-specific GLP-1R deficiency compared to control mice ([Figure 4](#fig4){ref-type="fig"}A). This occurred in the absence of differences in insulin secretion ([Figure S5](#mmc1){ref-type="supplementary-material"}A), fasting blood glucose levels ([Figure S5](#mmc1){ref-type="supplementary-material"}B), and central or peripheral GLP-1 levels between GLP-1R^ΔGFAP^ and control mice ([Figure S5](#mmc1){ref-type="supplementary-material"}C). Rather, improved glucose tolerance appears to result from enhanced hepatic glucose clearance ([@bib78]) as indicated by increased liver glycogen content in GLP-1R^ΔGFAP^ mice ([Figure S5](#mmc1){ref-type="supplementary-material"}D). Furthermore, mice with astrocyte-specific GLP-1R deficiency displayed improved insulin sensitivity as revealed by insulin tolerance tests ([Figure 4](#fig4){ref-type="fig"}B). In support of this finding, during hyperinsulinemic-euglycemic clamp studies, greater glucose infusion rates were needed during the steady state of the experiment ([Figure 4](#fig4){ref-type="fig"}C) to achieve similar glucose values in GLP-1R^ΔGFAP^ compared to control mice ([Figure S5](#mmc1){ref-type="supplementary-material"}E). Moreover, assessment of tissue-specific glucose uptake rates revealed enhanced glucose uptake in white adipose tissue (WAT) and a tendency toward increased glucose uptake in brown adipose tissue (BAT), while no difference was observed in skeletal muscle (SKM) or in the brain of GLP-1R^ΔGFAP^ mice ([Figure 4](#fig4){ref-type="fig"}D). In support of enhanced hepatic insulin sensitivity, insulin-dependent suppression of hepatic glucose production (HGP) was improved in mice lacking GLP-1R in astrocytes compared to littermate controls ([Figure S5](#mmc1){ref-type="supplementary-material"}F), while there was no difference in steady-state serum insulin levels between the genotypes ([Figure S5](#mmc1){ref-type="supplementary-material"}G). Nevertheless, these results cannot be fully interpreted in the presence of negative HGP values. However, analysis of hepatic insulin signaling, via assessing hepatic pAkt levels in post-clamp liver samples, also showed an increase in insulin-stimulated Akt signaling in these mice ([Figure 4](#fig4){ref-type="fig"}E). Insulin-stimulated Akt phosphorylation was also enhanced in BAT ([Figure 4](#fig4){ref-type="fig"}F), but not in WAT ([Figure 4](#fig4){ref-type="fig"}G) or SKM ([Figure 4](#fig4){ref-type="fig"}H), of GLP-1R^ΔGFAP^ mice. Of note, improvements in glucose metabolism were not due to differences in body weight ([Figure S5](#mmc1){ref-type="supplementary-material"}H) or body composition ([Figure S5](#mmc1){ref-type="supplementary-material"}I), nor did we observe differences in fasting plasma leptin levels ([Figure S5](#mmc1){ref-type="supplementary-material"}J) or organ weights ([Figure S5](#mmc1){ref-type="supplementary-material"}K) between the mice of different genotypes. Accordingly, food intake ([Figure S5](#mmc1){ref-type="supplementary-material"}L), fluid intake ([Figure S5](#mmc1){ref-type="supplementary-material"}M), energy expenditure (EE) ([Figure S5](#mmc1){ref-type="supplementary-material"}N), and locomotor activity ([Figure S5](#mmc1){ref-type="supplementary-material"}O) were not altered in GLP-1R^ΔGFAP^ mice compared to control mice.Figure 4Impaired Astrocyte GLP-1R Signaling Improves Systemic Glucose Homeostasis(A and B) Glucose tolerance test (A) and insulin tolerance test (B) in GLP-1R^ΔGFAP^ and control mice (n = 10--12 per genotype).(C and D) Glucose infusion rate (GIR) (C) and organ-specific glucose uptake rates (D) in perigonadal white adipose tissue (WAT), brown adipose tissue (BAT), skeletal muscle (SKM), and brain during hyperinsulinemic-euglycemic clamp studies (n = 9--10 per genotype).(E--H) Representative immunoblots showing phosphorylation of AKT (p-AKT) determined in clamped (E) liver, (F) BAT, (G) WAT, and (H) SKM samples of GLP-1R^ΔGFAP^ and control mice (n = 9--10 per genotype). Quantification of p-AKT levels was performed after normalization to total AKT and calnexin as loading control.Data are represented as mean ± SEM. ^∗^p ≤ 0.05, ^∗∗^p ≤ 0.01, ^∗∗∗^p ≤ 0.001 as determined by two-way ANOVA with repeated-measurements (time) followed by Bonferroni post hoc test (A--C) and two-tailed, unpaired Student's t test (D--H). See also [Figure S5](#mmc1){ref-type="supplementary-material"}.

CNS-Restricted Neutralization of FGF21 or Astrocyte-Specific Ablation of FGF21 Attenuates the Improvement of Glucose Metabolism in GLP-1R^ΔGFAP^ Mice {#sec3.5}
-----------------------------------------------------------------------------------------------------------------------------------------------------

Continuous intracerebroventricular infusion with FGF21 has been shown to increase glucose tolerance in lean rats without impacting body weight or body composition ([@bib84]). In line with an increase in *FGF21* expression upon GLP-1R ablation in primary astrocytes, we also found increased FGF21 protein expression in the hypothalamus of GLP-1R^ΔGFAP^ compared to control mice ([Figure 5](#fig5){ref-type="fig"}A). To unravel if the increase in central FGF21 mediated the improvements in systemic glucose handling in mice lacking GLP-1R expression in astrocytes, we injected mice of the different genotypes intracerebroventricularly (i.c.v.) with a neutralizing anti-FGF21 antibody ([@bib98]) prior to a glucose tolerance test. These experiments revealed that neutralization of FGF21 in the CNS abolished the improvements in glucose tolerance in astrocyte-specific GLP-1R-deficient mice, while it did not affect glucose tolerance in lean control mice ([Figure 5](#fig5){ref-type="fig"}B).Figure 5Neutralization of Central FGF21 or Astrocyte-Specific Ablation of FGF21 Attenuates Improvements in Glucose Metabolism in GLP-1R^ΔGFAP^ Mice(A) Representative immunoblot and quantification of FGF21 protein expression in hypothalamic extracts of GLP-1R^ΔGFAP^ and control mice. Quantification of FGF21 levels was performed after normalization to calnexin as loading control (n = 3--4 per genotype).(B) Glucose tolerance test (GTT) in GLP-1R^ΔGFAP^ and control mice upon intracerebroventricular injection with a neutralizing FGF21 antibody (AB) or vehicle (IgG AB) (n = 14--24 per group).(C) Representative confocal images of *in situ* hybridization of mRNA of *FGF21* (red), immunohistochemistry of GFAP (green), and corresponding nuclear counterstaining (DAPI, blue) in the arcuate nucleus of the hypothalamus (ARH) of GLP-1R^ΔGFAP^, GLP-1R;FGF21^ΔGFAP^, and control mice . Arrows indicate *FGF21*-positive, GFAP-double-positive cells. Scale bars, 100 μm.(D) Quantification of the percentage of *FGF21*-positive GFAP astrocytes per hemi-ARH (n = 8 animals per genotype).(E) GTT in GLP-1R^ΔGFAP^, GLP-1R;FGF21^ΔGFAP^, and control mice (n = 4--19 per genotype).Data are represented as mean ± SEM. ∗∗p ≤ 0.01 (A); ∗∗p ≤ 0.01, ∗∗∗p ≤ 0.001 (GLP-1R^∆GFAP^-vehicle versus control-vehicle), ^tt^p ≤ 0.01 (GLP-1R^∆GFAP^-FGF21 AB versus GLP-1R^∆GFAP^-vehicle) (B), ^§^p ≤ 0.05 (GLP-1R;FGF21^∆GFAP^ versus control), ^\#\#\#^p ≤ 0.001 (GLP-1R^∆GFAP^ versus GLP-1R;FGF21^∆GFAP^) (D); ^\#^p ≤ 0.05 (GLP-1R^∆GFAP^ versus GLP-1R;FGF21^∆GFAP^), ∗∗p ≤ 0.01 (GLP-1R^∆GFAP^ versus control) (E), as determined by unpaired two-tailed Student's t test (A) and by two-way ANOVA followed by Bonferroni post hoc test (B, D, and E).

To next assess if increased brain FGF21 resulting in improvements in glucose tolerance of astrocyte-specific GLP-1R-deficient mice was astrocyte derived, we crossed GLP-1R^ΔGFAP^ mice to FGF21^flox/flox^ mice ([@bib71]). Further intercrossing of these animals resulted in different littermate groups of mice: (1) control animals (GLP-1R^flox/flox^;FGF21^wt/wt^ and GLP-1R^flox/flox^;FGF21^flox/flox^ mice), (2) GLP-1R^ΔGFAP^ mice lacking GLP-1R in astrocytes, and (3) GLP-1R;FGF21^ΔGFAP^ mice lacking both GLP-1R and FGF21 expression in astrocytes upon tamoxifen application in adult mice. Astrocyte *FGF21* mRNA expression was investigated in control animals, GLP-1R^ΔGFAP^, and GLP-1R;FGF21^ΔGFAP^ mice via fluorescent *in situ* hybridization (RNAscope). This analysis revealed a significantly lower percentage of *FGF21*-expressing GFAP-positive astrocytes in GLP-1R;FGF21^ΔGFAP^ compared to control and GLP-1R^ΔGFAP^ mice ([Figures 5](#fig5){ref-type="fig"}C and 5D). Interestingly, improved glucose tolerance upon astrocyte-specific GLP-1R ablation was abolished in mice with simultaneous reduction of FGF21 expression in astrocytes ([Figure 5](#fig5){ref-type="fig"}E). Overall, these experiments revealed that increased astrocyte-derived FGF21 production functionally contributes to the improvements in glucose tolerance in GLP-1R^ΔGFAP^ mice.

Astrocyte-Specific GLP-1R Ablation Enhances Brain Glucose Availability {#sec3.6}
----------------------------------------------------------------------

As we observed increased glucose uptake in astrocytes upon GLP-1R deletion, we examined if brain glucose availability was altered in mice with astrocyte-specific GLP-1R ablation. In line with our *ex vivo* findings, assessment of brain glucose uptake via ^18^F-FDG PET scans revealed an increase in central glucose transport in various regions of the brain ([Figure 6](#fig6){ref-type="fig"}A) including the olfactory bulb ([Figure 6](#fig6){ref-type="fig"}B), the precommissural nucleus ([Figure 6](#fig6){ref-type="fig"}C), the hippocampus ([Figures 6](#fig6){ref-type="fig"}D, 6E, and 6I), the substantia nigra ([Figure 6](#fig6){ref-type="fig"}F), the hypothalamus ([Figure 6](#fig6){ref-type="fig"}G), and the reticular formation ([Figure 6](#fig6){ref-type="fig"}H), as well as in multiple other structures throughout the brain ([Figure S6](#mmc1){ref-type="supplementary-material"}A), like the piriform cortex ([Figure S6](#mmc1){ref-type="supplementary-material"}B), the caudate putamen ([Figure S6](#mmc1){ref-type="supplementary-material"}C), the lateral septum ([Figure S6](#mmc1){ref-type="supplementary-material"}D), the dorsal endopiriform nucleus ([Figure S6](#mmc1){ref-type="supplementary-material"}E), the periolivary nucleus ([Figure S6](#mmc1){ref-type="supplementary-material"}F), the sensory trigeminal nucleus ([Figure S6](#mmc1){ref-type="supplementary-material"}G), and the hindbrain ([Figure S6](#mmc1){ref-type="supplementary-material"}H), in overnight-fasted GLP-1R^ΔGFAP^ versus control mice. In contrast, glucose uptake was only very mildly increased or even decreased in distinct brain areas in non-fasted, random-fed GLP-1R^ΔGFAP^ mice compared to controls ([Figures S6](#mmc1){ref-type="supplementary-material"}I--S6N). Taken together, these findings indicate that reduction of GLP-1R expression in GFAP-expressing astrocytes enhances brain glucose availability dependent on the nutritional state of the organism.Figure 6Astrocyte-Specific GLP-1R Ablation Enhances Brain Glucose Availability(A) Images showing differential regional glucose uptake in 16 h-fasted GLP-1R^ΔGFAP^ versus control animals as determined by PET-CT. Color code represents the p value for the indicated voxels in an unpaired Student's t test in 16 h-fasted GLP-1R^ΔGFAP^ versus control animals for n = 10--11 animals per genotype. Increases in glucose uptake are shown in red.(B--I) Quantification of brain glucose uptake in 16 h-fasted GLP-1R^ΔGFAP^ versus control animals in the (B) olfactory bulb, (C) precommisural nucleus, (D) hippocampus CA1 anterior, (E) hippocampus CA2/CA3, (F) substantia nigra, (G) hypothalamus, (H) reticular formation, and (I) hippocampus CA1 dorsal.Results are presented as boxplots. Upper and lower whiskers indicate the minimum and maximum values of the data, center lines indicate the median, and plus signs indicate the mean values. ^∗^p ≤ 0.05, ^∗∗^p ≤ 0.01 as determined by unpaired two-tailed Student's t test (B--I). See also [Figures S6--S8](#mmc1){ref-type="supplementary-material"}.

As GLP-1 acutely reduced glucose uptake in primary astrocytes *in vitro* ([Figure S2](#mmc1){ref-type="supplementary-material"}B), we next aimed to assess if acute central application of GLP-1 impacts brain glucose uptake in overnight-fasted mice *in vivo*. To this end, fasted C57Bl6/N mice were acutely injected i.c.v. with 1 μg GLP-1. Assessment of brain glucose uptake via ^18^F-FDG PET scans revealed a decrease in central glucose transport in distinct regions of the brain ([Figure S7](#mmc1){ref-type="supplementary-material"}A) like the lateral septum ([Figure S7](#mmc1){ref-type="supplementary-material"}B), the hypothalamus ([Figure S7](#mmc1){ref-type="supplementary-material"}C), and the dorsal hippocampus ([Figure S7](#mmc1){ref-type="supplementary-material"}D), in line with previous reports showing a decrease in brain glucose uptake upon acute GLP-1 administration in overnight-fasted healthy volunteers ([@bib4], [@bib50]). Of note, the decrease in central glucose uptake upon acute intracerebroventricular injection of GLP-1 was abrogated in fasted GLP-1R^ΔGFAP^ mice ([Figures S7](#mmc1){ref-type="supplementary-material"}H--S7K) compared to control mice ([Figures S7](#mmc1){ref-type="supplementary-material"}E--S7G). Thus, our experiments revealed that acute activation of cerebral GLP-1 signaling in the fasting state decreases brain glucose uptake in various regions of the brain in an astrocyte-dependent manner.

Ablation of GLP-1R in Hypothalamic GFAP Astrocytes Improves Hypothalamic Glucose Availability and Systemic Glucose Metabolism {#sec3.7}
-----------------------------------------------------------------------------------------------------------------------------

We next intended to investigate if postnatal ablation of GLP-1R signaling specifically in hypothalamic astrocytes of the ARH recapitulates the improved glucose-regulatory phenotype of GLP-1R^ΔGFAP^ mice. To this end, we used a viral-mediated Cre/loxP approach as previously described ([@bib26]) to ablate GLP-1R expression in GFAP-expressing astrocytes within the ARH. First, we confirmed that viral delivery to the ARH of GLP-1R^flox/flox^ mice resulted in GFP expression specifically in astrocytes of the ARH ([Figures S8](#mmc1){ref-type="supplementary-material"}A and S8B). Furthermore, immunohistochemistry using liraglutide^594^ revealed staining of liraglutide^594^ in astrocytes of the ARH of control virus-treated mice, which was reduced in Cre virus-treated animals ([Figures S8](#mmc1){ref-type="supplementary-material"}C and S8D). ^18^F-FDG PET scans in overnight-fasted mice revealed a marked increase in central glucose transport in the hypothalamus of mice with GLP-1R ablation in hypothalamic astrocytes ([Figures S8](#mmc1){ref-type="supplementary-material"}E and S8F). In addition, deletion of GLP-1R in the ARH of adult mice resulted in improved glucose handling during a glucose tolerance test ([Figure S8](#mmc1){ref-type="supplementary-material"}G) and enhanced insulin sensitivity during an insulin tolerance test ([Figure S8](#mmc1){ref-type="supplementary-material"}H). Overall, these results revealed that ablation of GLP-1R signaling in ARH astrocytes largely recapitulated the improvements in brain and peripheral glucose handling observed in GLP-1R^ΔGFAP^ mice.

Astrocyte-Specific GLP-1R Deficiency Enhances Memory Formation in Part via FGF21 and Enhances Spontaneous Activity of Dopaminergic Midbrain Neurons {#sec3.8}
---------------------------------------------------------------------------------------------------------------------------------------------------

Decreased brain glucose uptake has been linked to cognitive impairment ([@bib37]) and determines progression of neurodegenerative disorders such as Alzheimer's disease ([@bib30], [@bib104]). Accordingly, brain glucose availability, astrocyte glycolysis-derived lactate, and astrocyte-neuron lactate shuttling are required for long-term memory formation ([@bib12], [@bib63], [@bib74], [@bib94]). Therefore, we investigated if increased brain glucose availability in GLP-1R^ΔGFAP^ mice and enhanced astrocyte glucose uptake and glycolytic capacity in GLP-1R-deficient astrocytes translate into alterations in memory formation. To this end, astrocyte-specific GLP-1R-deficient and control mice were assessed in a spatial memory task. Indeed, GLP-1R^ΔGFAP^ mice performed significantly better compared to control mice during a Morris water maze task ([Figure 7](#fig7){ref-type="fig"}A) both during the learning phase and during the retention trial, the latter of which was more pronounced when mice were fasted before the retention trial ([Figure 7](#fig7){ref-type="fig"}B) compared to random-fed mice ([Figure S9](#mmc1){ref-type="supplementary-material"}A). Of note, no difference in anxiety-related behavior ([Figure S9](#mmc1){ref-type="supplementary-material"}B) or motor coordination ([Figure S9](#mmc1){ref-type="supplementary-material"}C) was observed between the genotypes. As FGF21 has been shown to improve memory formation ([@bib81], [@bib80], [@bib102]), we next investigated if the improvement in memory formation in astrocyte-specific GLP-1R-deficient mice was mediated, at least in part, via FGF21. To this end, GLP-1R^ΔGFAP^, GLP-1R;FGF21^ΔGFAP^, and control mice were subjected to the same spatial memory learning task. Interestingly, enhanced memory formation in GLP-1R^ΔGFAP^ mice was reduced in mice lacking FGF21 in addition to GLP-1R in astrocytes ([Figures 7](#fig7){ref-type="fig"}C and 7D). Again, no differences in anxiety-related behavior ([Figure S9](#mmc1){ref-type="supplementary-material"}D) or motor coordination ([Figure S9](#mmc1){ref-type="supplementary-material"}E) were observed between the genotypes.Figure 7Astrocyte-Specific GLP-1R Deficiency Enhances Memory Formation in an FGF21-Dependent Manner(A) Representative swimming task and quantification of escape latency during the indicated training days of a Morris water maze task of random-fed GLP-1R^ΔGFAP^ and control mice (n = 17 per genotype).(B) Representative swimming task and quantification of time spent in the target quadrant during retention trial upon 16 h overnight fasting (n = 6--8 per genotype) at day 10 of the Morris water maze task as described in (A).(C) Representative swimming task and quantification of escape latency during the indicated training days of a Morris water maze task of random-fed GLP-1R^ΔGFAP^, GLP-1R;FGF21^ΔGFAP^, and control mice (n = 4--6 per genotype).(D) Representative swimming task and quantification of time spent in the target quadrant during retention trial upon 16 h overnight fasting at day 10 (n = 4--6 per genotype) of the Morris water maze task as described in (C).Data are represented as mean ± SEM. ^∗^p ≤ 0.05, ^∗∗∗^p ≤ 0.001 as determined by two-way ANOVA followed by Tukey's post hoc test (A, C, and D) and unpaired two-tailed Student's t test (B). See also [Figures S9](#mmc1){ref-type="supplementary-material"} and [S10](#mmc1){ref-type="supplementary-material"}.

It is often difficult to associate complex behaviors directly and causally with a single neuron type. Here, we used the dopaminergic neurons of the midbrain as an indicator population to investigate whether neurons involved in memory formation are modulated in GLP-1R^ΔGFAP^ mice. We have chosen this neuron population because it is essential for memory formation and because it can be identified in native brain slices without the need for the generation of specific genetically modified mouse models ([Figures S10](#mmc1){ref-type="supplementary-material"}B and S10C). The midbrain, comprised of the ventral tegmental area (VTA) and the substantia nigra pars compacta (SNc), has been uncovered as an essential component for memory formation independent of the hippocampus ([@bib15], [@bib16], [@bib64], [@bib79]). Furthermore, midbrain astrocyte metabolism plays a major role in supporting the dopaminergic neurons of the SN ([@bib45], [@bib46]). In line, the excitability of dopaminergic SN neurons can be modulated by K~ATP~ channels, which is crucial for novelty-induced exploratory behavior ([@bib85]), and glucose enhances the spontaneous activity of dopaminergic SN neurons ([@bib56]). Very recently it has been demonstrated that VTA astrocytes selectively alter local GABA neurons to modulate learned behavior ([@bib28]). Thus, we hypothesized that spontaneous activity in dopaminergic midbrain neurons might be altered due to enhanced local glucose uptake in the midbrain in GLP-1R^ΔGFAP^ mice ([Figure 6](#fig6){ref-type="fig"}F). *In situ* hybridization revealed *GLP-1R* expression in GFAP astrocytes in close proximity to the SN in C57BL6/N mice ([Figure S10](#mmc1){ref-type="supplementary-material"}A). To assess whether the activity of dopaminergic neurons is changed, we analyzed spontaneous firing of synaptically isolated dopaminergic SNc neurons in adult overnight-fasted GLP-1R^ΔGFAP^ and control mice ([Figures S10](#mmc1){ref-type="supplementary-material"}B and S10C). To conserve the integrity of the cytosolic pathways, the recordings were performed in the perforated patch-clamp configuration. For post hoc identification, cells were loaded with biocytin by converting the perforated patch configuration to the whole-cell configuration at the end of the recording and tested for tyrosine hydroxylase immunoreactivity ([Figure S10](#mmc1){ref-type="supplementary-material"}B). These studies revealed that spontaneous firing of SNc neurons from GLP-1R^ΔGFAP^ compared to control mice indeed showed an enhanced spontaneous firing frequency ([Figure S10](#mmc1){ref-type="supplementary-material"}D) as well as a smaller coefficient of variance indicating improved intrinsic pace-making properties ([Figure S10](#mmc1){ref-type="supplementary-material"}E), possibly contributing to the observed improvements in learning and memory formation in GLP-1R^ΔGFAP^ mice.

Taken together, these results revealed that ablation of GLP-1R signaling in GFAP-expressing astrocytes results in improved memory formation, at least in part mediated via enhanced astrocyte-derived FGF21 and in parallel to enhanced spontaneous activity of SNc neurons.

Discussion {#sec4}
==========

Mitochondria play a pivotal role in nutrient sensing and in the coordination of adaptive feedback mechanisms of hypothalamic neurons in the regulation of central energy and glucose homeostasis ([@bib62], [@bib101]). Several recent studies have uncovered that astrocytes, apart from neurons, actively contribute to the control of central and systemic energy metabolism ([@bib25], [@bib26], [@bib41], [@bib100], [@bib105], [@bib107]). However, the role of mitochondrial function in astrocyte nutrient sensing and astrocyte-mediated energy and glucose homeostasis control remained largely elusive. Here we demonstrate that GLP-1R signaling is required for maintaining mitochondrial integrity and function in astrocytes, specifically at the level of the hypothalamus. Lack of GLP-1R signaling in hypothalamic astrocytes mildly impairs mitochondrial function and induces a cellular stress response, associated with increased FGF21 production, which results in an improvement in brain and systemic glucose homeostasis and enhanced memory formation.

Our findings are in line with the general observation that functional impairment of mitochondria promotes an integrated stress response, which is regulated via the transcription factor ATF4 ([@bib59], [@bib72]). The canonical stress pathway induced by ATF4 leads to the upregulation of distinct ATF4 target genes like *ATF5* ([@bib59], [@bib108]) and *FGF21* ([@bib17], [@bib40], [@bib108]), a mechanism conserved across various different cell types ([@bib39], [@bib40], [@bib69], [@bib99]), including neurons ([@bib76]). FGF21 is therefore evaluated as a possible biomarker in mitochondrial disease ([@bib11], [@bib49], [@bib61], [@bib92]).

However, besides its characteristics as a marker for mitochondrial dysfunction, FGF21 is a metabolically active polypeptide physiologically released by the liver and WAT in response to nutrient starvation ([@bib8], [@bib36]). Moreover, FGF21 is also expressed in a variety of other different organs including muscle, pancreas, testes, heart, thymus, and brain ([@bib22]). The systemic, metabolism-regulatory effects of FGF21 are complex and depend not only on the tissue-specific context but also on the metabolic status of the organism ([@bib71]). FGF21 derived from the periphery can cross the blood-brain barrier to act in the brain, but it is also expressed in the hypothalamus ([@bib51]). At the level of the CNS, FGF21 has been shown to impact systemic metabolic homeostasis as well as neuroprotection and cognition ([@bib18], [@bib80], [@bib102]). Increased cerebral FGF21 levels upon continuous intracerebroventricular infusion of recombinant FGF21 enhance glucose tolerance and increase hepatic glycogen content in rats ([@bib84]). Accordingly, enhanced production of astrocyte-derived FGF21 in mice with astrocyte-specific GLP-1R ablation resulted in improvements in systemic glucose metabolism, while we did not observe changes in body weight, body composition, or EE. Thereby, our results are in line with previous reports showing that central overexpression or prolonged central administration of FGF21 does not alter EE, body weight, or body composition in lean animals while it enhances EE and reduces body weight in obese rodents ([@bib66], [@bib84]).

Although the improvement of brain and systemic glucose metabolism in the absence of functional GLP-1R signaling in astrocytes may appear counterintuitive in light of the beneficial metabolism-regulatory effects of GLP-1 action as well as evidence for its neuroprotective role in neurodegenerative diseases, these beneficial effects are well explained by the non-cell-autonomous effects of activating a stress response and are, at least in part, mediated through the release of FGF21. Thus, the fundamental role of GLP-1 in astrocytes appears to be its herein uncovered necessity to adapt mitochondrial dynamics, function, and fuel utilization to systemic energy availability, while the observed systemic metabolic effects arise from a compensatorily activated stress response. In fact, we view our results in line with the evolutionary conservation of such response as initially revealed already in *C. elegans*. Here it has been shown that mild impairment of mitochondrial function in neurons can initiate a non-cell-autonomous stress response, which even extends longevity in this model organism ([@bib20]). Thus, we provide evidence that in astrocytes of mammals, activation of a mitochondrial stress response caused by impairment of GLP-1 action may also elicit beneficial systemic effects. Collectively, the results of our study uncovered a critical role of GLP-1R signaling in the maintenance of astrocyte mitochondrial integrity and unveiled how the astrocyte mitochondrial stress response impacts systemic and brain glucose homeostasis as well as memory formation.

Limitations of Study {#sec4.1}
--------------------

While our *in vitro* studies in cultured primary astrocytes clearly demonstrate a previously unrecognized role for GLP-1 signaling to regulate fuel utilization as well as mitochondrial dynamics and function in this cell type, the overall metabolic changes observed upon astrocyte-restricted reduction of GLP-1R-signaling *in vivo* appear to arise from the activation of an integrated stress response and are, at least in part, mediated by increased astrocyte-derived FGF21 acting in the CNS. While these results highlight the functional significance of GLP-1R signaling for controlling astrocyte mitochondrial function *in vivo*, this leaves open what the direct physiological consequences of GLP-1R action in this cell type are *in vivo*. Here, further extensive studies of mice with reduced GLP-1R and FGF21 expression in astrocytes may highlight the physiological consequences of reduced astrocyte GLP-1R signaling when at the same time the compensatory stress response is attenuated.

Moreover, most of the conclusions of the current study are derived from either cultured astrocytes in the presence or absence of altered GLP-1R signaling or mice with astrocyte-specific deletion of the GLP-1R, thereby limiting our experimental models to cell-type-selective GLP-1R deficiency. Thus, reconstitution experiments re-expressing the GLP-1R specifically in astrocytes of conventional GLP-1R knockout mice may provide another avenue for future investigation to further define the physiological role of GLP-1R action in astrocytes.

STAR★Methods {#sec6}
============

Key Resources Table {#sec6.1}
-------------------

REAGENT or RESOURCESOURCEIDENTIFIER**Antibodies**Anti-NDUFA9 (Complex I)Invitrogen, Thermo Fisher ScientificCat\# 459100; RRID: [AB_2532223](nif-antibody:AB_2532223){#intref0010}Anti-NDUFB8 (Complex I)Invitrogen, Thermo Fisher ScientificCat\# 459210; RRID: [AB_2532232](nif-antibody:AB_2532232){#intref0015}Anti-Complex II 70 kDa Fp SubunitInvitrogen, Thermo Fisher ScientificCat\# 459200; RRID: [AB_2532231](nif-antibody:AB_2532231){#intref0020}Anti-UQCRC1 (Complex III)Invitrogen, Thermo Fisher ScientificCat\# 459140; RRID: [AB_2532227](nif-antibody:AB_2532227){#intref0025}Anti-Subunit Va (Complex IV)Invitrogen, Thermo Fisher ScientificCat\# 459110; RRID: [AB_2532224](nif-antibody:AB_2532224){#intref0030}Anti-ATP synthase subunit β (Complex V)Invitrogen, Thermo Fisher ScientificCat\# 21351; RRID: [AB_221512](nif-antibody:AB_221512){#intref0035}Anti-calnexinMerck MilliporeCat\# 208880; RRID: [AB_2069031](nif-antibody:AB_2069031){#intref0040}Anti-GLUT-1Merck MilliporeCat\# 07-1401; RRID: AB_1340Anti-pGLUT-1 (Ser-226)Merck MilliporeCat\# ABN991Anti-TOM20Cell SignalingCat\# sc-11415; RRID: [AB_2207533](nif-antibody:AB_2207533){#intref0045}Anti-GFAPAbcamCat\# 7260; RRID: [AB_305808](nif-antibody:AB_305808){#intref0050}Anti-AktCell SignalingCat\# 4685; RRID: [AB_2225340](nif-antibody:AB_2225340){#intref0055}Anti-pAkt (S473)Cell SignalingCat\# 4060; RRID: [AB_2315049](nif-antibody:AB_2315049){#intref0060}Anti-FGF21R&D SystemsCat\# AF3057; RRID: [AB_2104611](nif-antibody:AB_2104611){#intref0065}Anti-IgG ControlR&D SystemsCat\# AB-108-C; RRID: [AB_354267](nif-antibody:AB_354267){#intref0070}Anti-GLP-1RNovus BiologicalsCat\# NBP1-97308; RRID: [AB_11139100](nif-antibody:AB_11139100){#intref0075}Anti-GFPAbcamCat\# 13970; RRID: [AB_300798](nif-antibody:AB_300798){#intref0080}Anti-THAbcamCat\# 76442; RRID: [AB_1524535](nif-antibody:AB_1524535){#intref0085}Alexa 488 donkey-anti-rabbitThermo Fisher ScientificCat\# A-21206; RRID: [AB_2535792](nif-antibody:AB_2535792){#intref0090}Alexa 488 goat-anti-rabbitThermo Fisher ScientificCat\# A-11008; RRID: [AB_143165](nif-antibody:AB_143165){#intref0095}FITC goat-anti-chickenJackson LaboratoriesCat\# 103-095-155; RRID: [AB_2337384](nif-antibody:AB_2337384){#intref0100}Alexa 647 donkey-anti-rabbitThermo Fisher ScientificCat\# A-31573; RRID: [AB_2536183](nif-antibody:AB_2536183){#intref0105}Alexa 633--conjugated streptavidinInvitrogen, Thermo Fisher ScientificCat\# S-21375; RRID: [AB_2313500](nif-antibody:AB_2313500){#intref0110}Dylight 488 anti-chicken IgGAbcamCat\# 96947; RRID: [AB_10681017](nif-antibody:AB_10681017){#intref0115}**Bacterial and Virus Strains**AAV5-GFAP(2.2)-iCreVector BioLabsVB1172AAV5-GFAP(2.2)-eGFPVector BioLabsVB1180**Chemicals, Peptides, and Recombinant Proteins**AdenoBOOSTSirion BiotechCat\# SB-P-AV-101-02BiocytinSigma-AldrichCat\# B4261DAPI-containing vectashieldVector LaboratoriesCat\# VEC-H-1200GLP-1 7-36 amideBachemCat\# H-6795WZB117Sigma AldrichCat\# SML062120% Glucosebela-pharmCat\# 2069.97.99InsulinSanofi Aventis, GermanyInsuman rapidLiraglutide^594^Novo NordiskN/ASeahorse XF Palmitate-BSA FAO SubstrateAgilent TechnologiesCat\# 102720-100TamoxifenSigma-AldrichCat\# T5648-5GTSA Plus Cyanine 3Perkin ElmerCat\# NEL744E001KTTSA Plus Cyanine 5Perkin ElmerCat\# NEL745E001KTChemicals used in Primary Cell CulturesDMEM high glucose, GlutaMAXGIBCO, ThermoFisher ScientificCat\# 10569010DMEMGIBCO, ThermoFisher ScientificCat\# 11966-025Fetal Bovine Serum (FBS)Pan BiotechCat\# P30-3302Penicillin/StreptomycinGIBCO, ThermoFisher ScientificCat\# 15140-122HBSS, no calcium, no magnesiumInvitrogen, ThermoFisher ScientificCat\# 14170112L-15 mediumGIBCO, ThermoFisher ScientificCat\# 11415064D-(+)-Glucose solution 45% in H2OSigma-AldrichCat\# G8769L-Carnitine hydrochlorideSigma-AldrichCat\# C0283-1GEtomoxirSigma-AldrichCat\# E1905-25MGHEPES solutionSigma-AldrichCat\# H0887-100MLPoly-L-LysineSigma-AldrichCat\# P-4707**Critical Commercial Assays**QIAshredder (250)QIAGENCat\# 79656RNeasy Mini Kit (250)QIAGENCat\# 74106Applied Biosystems High-Capacity CDNA Reverse Transcription KitThermo Fisher ScientificCat\# 4368813Applied Biosystems TaqMan Universal PCR Master MixThermo Fisher ScientificCat\# 10733457Mouse GLP-1 ELISACrystal Chem, USACat\# 81508Mouse ultra-sensitivity insulin ELISACrystal Chem, USACat\# 90080Human Ultrasensitive Insulin ELISADRG Instruments GmbHCat\# EIA-2337Mouse Leptin ELISACrystal Chem, USACat\# 90030Picoprobe Glucose AssayAbcamCat\# ab169559Glucose Uptake Cell-Based AssayCayman Chemical, USACat\# Cay-600470Pierce BCA Protein AssayThermo Fisher ScientificCat\# 23225L-Lactate AssayAbcamab65331Dental acrylic Super Bond C&BSun MedicalCat\# 7100XF Cell Mito Stress Test KitAgilent TechnologiesCat\# 101706-100TSA Plus Fluorescence kitPerkin Elmer, USACat\# NEL741001KTRNAscope Enhancer Fluorescent Kit v2ACDCat\# 323100**Experimental Models: Organisms/Strains**Mouse: C57BL/6NCharles RiverN/AMouse: hGFAP-CreERT2([@bib24])N/AMouse: GLP-1R-flox([@bib38])N/AMouse: GLP-1R deficient (GLP-1R^Δ/Δ^)([@bib89])N/AMouse: FGF21-flox([@bib71])N/A**Oligonucleotides**Taqman probe m*GLP1-R*ThermoFisher ScientificMm00445292_m1Taqman probe *HPRT*ThermoFisher ScientificMm01545399_m1Taqman probe *ATF4*ThermoFisher ScientificMm00515324_m1Taqman probe *ATF5*ThermoFisher ScientificMm04179654_m1Taqman probe *Ddit3 (CHOP)*ThermoFisher ScientificMm00492097_m1Taqman probe *Hspa5 (BIP)*ThermoFisher ScientificMm00517691_m1Taqman probe *Ppara (PPARα)*ThermoFisher ScientificMm00440939_m1Taqman probe *FGF21*ThermoFisher ScientificMm00840165_g1Custom-designed qPCR probes targeting hGLP1-R construct: Flag primer 5′ 913: GGACTACAAGGATGACGACGAC, 3′ 3580-152: CCCAAGGCACACAAAA\
AACC and mUTRprobe: 5′ FAM\
TGGCCATCCCAGGTGGGAGAGA\
TCCT 3′TAMRAEurogentec<https://secure.eurogentec.com/life-science.html>mitochondrial Nd2: fw: 5′- AGGG\
ATCCCACTGCACATAG-3′; rev: 5′- CTCCTCATGCCCCTATGAAA-3′Eurogentec<https://secure.eurogentec.com/life-science.html>mitochondrial D-Loop: fw: 5′- GGTTC\
TTACTTCAGGGCCATCA-3′, rev: 5′-\
GATTAGACCCGATACCATCGAGAT-3′Eurogentec<https://secure.eurogentec.com/life-science.html>nuclear Nduv: fw: 5′- CTTCCC\
CACTGGCCTCAAG-3′; rev: 5′-\
CCAAAACCCAGTGATCCAGC-3′Eurogentec<https://secure.eurogentec.com/life-science.html>Custom-designed RNA scope probe targeting the region 108 - 1203 of the *GLP1R* transcriptACDCat\# NM_021332.2Custom-designed RNA scope probe targeting the region 5 - 904 of the *FGF21* transcriptACDCat\# NM_020013.4**Software and Algorithms**GraphPad Prism 6 and 7GraphPad<https://www.graphpad.com/scientific-software/prism/>Fiji (ImageJ) Software Package (incl. Adiposoft Plugin)([@bib87])<https://imagej.net/Adiposoft>IVIS LivingImage Software V4.3.1Caliper LifeScience, Perkin Elmer, USA<https://www.perkinelmer.de/category/in-vivo-imaging-software>Vinci software package 4.61.0([@bib14])<https://vinci.sf.mpg.de/>TargetLynx SoftwareWaters<https://www.waters.com/waters/library.htm?locale=en_US&lid=1545580>Wave DesktopAgilent Technologies<https://www.agilent.com/en/products/cell-analysis/cell-analysis-software/data-analysis/wave-desktop-2-6>PatchMaster (version 2.32)HEKA, Lambrecht, Germany<https://www.heka.com/downloads/downloads_main.html>Patcher's Power Tools plug-inMPI, Neher Lab; programmed in IGOR Pro 6, Wavemetrics, Lake Oswego, OR, USA<https://www.mpibpc.mpg.de/groups/neher/index.php?page=software>CED 1401 with Spike2 (version 7)Cambridge Electronic Design Ltd., Cambridge, UK<http://ced.co.uk/de/>**Other**Regular Chow Dietsniff Spezialdiäten GmbH, GermanyR/M-H phytoestrogen-lowIVIS Spectrum CT scannerCaliper LifeScience, Perkin Elmer, USACat\# 128201Indirect calorimetry system ''PhenoMaster''TSE systems, Chesterfield, USA<http://www.tse-systems.com/products/metabolism/home-cage/phenomaster/index.htm>XFe96 Extracellular Flux Analyzer, "Seahorse"Agilent Technologies<https://www.agilent.com/en/products/cell-analysis/seahorse-analyzers/seahorse-xfe96-analyzer>Inveon preclinical PET/CT systemSiemensN/ADionex ICS-6000 HPIC systemThermo Fisher Scientific<https://www.thermofisher.com/de/de/home/industrial/chromatography/ion-chromatography-ic/ion-chromatography-systems/modular-ic-systems.html>Vibrating Microtome VT1200sLeica Microsystems<https://www.leicabiosystems.com/histology-equipment/sliding-and-vibrating-blade-microtomes/vibrating-blade-microtomes/leica-vt1200-s/>Leica TCS SP-8-X Confocal microscopeLeica Microsystems<https://www.leica-microsystems.com/products/confocal-microscopes/p/leica-tcs-sp8-x/>AB-QuantStudio 7 FlexApplied Biosystems, Thermo Fischer ScientificCat\# 4485701Inline solution heaterWarner Instruments, Hamden, CT, USACat\# SH27BTemperature controllerWarner Instruments, Hamden, CT, USACat\# TC-324BElectrode glassScience ProductsCat\# GB150-8PVertical pipette pullerNarishige, London, UKCat\# PP-830EPC10 patch-clamp amplifierHEKA, Lambrecht, Germany<https://www.heka.com/>

Resource Availability {#sec6.2}
---------------------

### Lead Contact {#sec6.2.1}

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Jens C. Brüning (<bruening@sf.mpg.de>).

### Materials Availability {#sec6.2.2}

No unique reagents were generated in this study.

### Data and Code Availability {#sec6.2.3}

There were no datasets generated in this study.

Experimental Model and Subject Details {#sec6.3}
--------------------------------------

### Animal Care {#sec6.3.1}

All animal procedures were conducted in compliance with protocols approved by the local government authorities (Bezirksregierung Köln) and were in accordance with NIH guidelines. Mice were housed in groups of 3--5 at 22 C°--24 C° using a 12-h light/12-h dark cycle. Animals had *ad libitum* access to water and the prescribed diet at all times, and food was only withdrawn if required for an experiment. Animals were fed a regular chow diet containing 57% calories from carbohydrates, 34% calories from protein, and 9% calories from fat (R/M-H; Sniff Diet). For all experiments only male mice were used. All experiments were performed in adult mice at the age of 16-28 weeks.

### Generation of Transgenic Mice {#sec6.3.2}

#### GLP-1R^ΔGFAP^ Mice {#sec6.3.2.1}

hGFAP-CreERT2 mice were mated with GLP-1R^flox/flox^ mice ([@bib38]) and breeding colonies were maintained by mating GLP-1R^flox/flox^ females to hGFAP-CreERT2; GLP-1R^flox/flox^ males. Mice were kept on a C57BL/6 background throughout the experiment. Tamoxifen application was performed at 8-9 weeks of age as previously described ([@bib43]).

#### GLP-1R;FGF21^ΔGFAP^ {#sec6.3.2.2}

GLP-1R^ΔGFAP^ mice were mated with FGF21^flox/flox^ mice ([@bib71]) and breeding colonies were maintained by mating hGFAP-CreERT2^tg/wt^; GLP-1R^flox/flox^; FGF21^flox/wt^ to hGFAP-CreERT2^wt/wt^; GLP-1R^flox/flox^; FGF21^flox/wt^ mice. Tamoxifen application at 8-9 weeks of age allowed for postnatal deletion of either only GLP-1R or GLP-1R and FGF21 in GFAP-expressing astrocytes (resulting littermate groups of mice: (1) control animals (GLP-1R^flox/flox^;FGF21^wt/wt^ and GLP-1R^flox/flox^;FGF21^flox/flox^, i.e. hGFAP-CreERT2-negative mice), (2) GLP-1R^ΔGFAP^ mice lacking GLP-1R expression in astrocytes and (3) GLP-1R;FGF21^ΔGFAP^ lacking both GLP-1R and FGF21 expression in astrocytes).

#### GLP-1R^Δ/Δ^ Mice {#sec6.3.2.3}

Whole-body male GLP-1R-deficient mice (GLP-1R^Δ/Δ^ mice) ([@bib89]) were kindly provided by Daniel J. Drucker.

#### C57Bl6/N Mice {#sec6.3.2.4}

Male C57Bl6/N mice were purchased from Charles River.

### Isolation and Culturing of Primary Hypothalamic Mouse Astrocytes {#sec6.3.3}

Hypothalamic explants were isolated from male pups at postnatal day 1-3 and were dissociated to single cells as follows: hypothalamic explants were isolated and meninges were carefully removed using an ultrafine forceps under the microscope. Afterward, the hypothalamic explants were transferred to ice-cold L-15 medium (\#11415064, GIBCO, ThermoFisher Scientific) and dissected using a sharp blade. Hypothalamic tissue pieces were then transferred to pre-warmed HBSS medium (\#14170112, GIBCO, ThermoFisher Scientific) and placed into the incubator at 37°C for 10 min with intermittent slight movement. Afterward, tissue pieces were transferred to a 15 mL falcon with 1X HBSS + 0.25% of trypsin (final volume 5 ml) and incubated at 37°C for 20 min with intermittent movement. Thereafter, the falcon was centrifuged at 1500 rpm for 5 min at 37°C. The supernatant was carefully discarded and complete medium (containing of DMEM high glucose, GlutaMAX supplement, \#10569010, GIBCO, ThermoFisher Scientific) supplemented with 10% heat-inactivated fetal bovine serum (FBS, \#P30-3302, PAN Biotech) and 1% penicillin/streptomycin (\#15140-122, GIBCO, ThermoFisher Scientific) was added and the pellet was gently dissociated by pipetting up-and-down before another centrifugation at 1500 rpm for 5 min at 37°C. Afterward, the supernatant was carefully discarded, complete medium was added and the pellet was again gently dissociated by pipetting up-and-down. After another centrifugation at 1500 rpm for 5 min at 37°C and after discarding the supernatant, cells were dissociated again in complete medium, counted and seeded in 25cm^2^ flasks with complete medium at 5% CO2, 37°C. After 8 days in culture, flasks were shaken on an orbital shaker at 180 rpm for 30 min to remove microglia ([@bib86]). After exchanging the medium, flasks were shaken for additional 6 h at 240 rpm to remove oligodendrocyte precursor cells ([@bib86]), followed by an additional medium change and further culturing.

Method Details {#sec6.4}
--------------

### Glucose Tolerance and Insulin Tolerance Tests {#sec6.4.1}

#### Glucose Tolerance Tests {#sec6.4.1.1}

Glucose tolerance tests were performed in the morning after an overnight fasting period of 16 h. Glucose concentrations in blood were measured from whole venous blood using an automatic glucose monitor (Bayer Contour, Bayer, Germany). After the fasting period, each mouse received an intraperitoneal injection of 20% glucose (2 g per kg body weight; bela-pharm) and blood glucose concentrations were measured before and after 15, 30, 60 and 120 min.

#### Insulin Tolerance Tests {#sec6.4.1.2}

Insulin tolerance tests were performed in the morning in random fed mice. After determination of basal blood glucose concentrations, each mouse received an intraperitoneal injection of insulin (0.375 U per kg body weight; Insuman Rapid; Sanofi Aventis) and glucose concentrations in the blood were measured after 15, 30, 60 and 120 min.

### Serum Analyses {#sec6.4.2}

Serum insulin and leptin levels were measured by enzyme-linked immunosorbent assay according to vendor's instructions (mouse ultra-sensitive Insulin ELISA, mouse Leptin ELISA; Crystal Chem, USA).

### Analysis of Total GLP-1 in Hypothalamic Explants, the Rest-Brain and in Plasma {#sec6.4.3}

Hypothalamic explants and rest-brains were lysed in lysis buffer (150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% TritonX and 0.5% sodium deoxycholate) and were homogenized using an homogenizer (IKA T10 basic Ultra Turrax). Then, homogenized samples were incubated for 1 h at 4°C and centrifuged at 3000 g, for 10 min at 4°C. Supernatants were collected and stored at −80°C. To measure the amount of GLP-1 in plasma, blood from random-fed animals was collected in tubes which contained EDTA, centrifuged at 10000 rpm for 10 min at 4°C and stored at −80°C. Afterward, total GLP-1 content in homogenized hypothalamic explants, the rest-brain and plasma was assessed using a mouse GLP-1 ELISA according to vendor's instructions (Crystal Chem, USA). The GLP-1 amount in the hypothalamic and the rest-brain samples was normalized to sample protein concentrations measured via the Pierce BCA Protein Assay Kit (Thermo Fischer).

### Liver Glycogen Measurement {#sec6.4.4}

Liver glycogen was assessed in random-fed GLP-1R^ΔGFAP^ and control mice as previously described ([@bib9], [@bib67]). In brief, liver samples were incubated in pre-cooled (4°C) 0.5 M PCA (perchloride acid, readymade, diluted in ddH2O) and incubated on ice for min 20 min. Thereafter, samples were centrifuged at 3000 rpm 15 min at 4°C. Afterward, the supernatant was removed and acidified with 1 M HCl and then boiled at 100°C for 2 h. Following, 10 M NaOH + 1 M HEPES were added and samples were centrifuged at 13000 rpm, 20 min, 4°C. The supernatant was removed and assessed for protein content using the Pierce BCA Protein Assay Kit (Thermo FischerScientific) kit and for glucose content using the Picoprobe Glucose Assay kit (Abcam).

### Euglycemic-Hyperinsulinemic Clamp Studies in Awake, Free-Moving Animals {#sec6.4.5}

Implantation of catheters into the jugular vein and the clamp procedure employed were performed as described before ([@bib44], [@bib97]). In brief, mice were anesthetized using a ketamine-dexmedetomidine combination and then a saline filled catheter (Micro-Renathane, MRE 025; Braintree Scientific, Braintree, Massachusetts, USA) was inserted into the right internal jugular vein and advanced to the level of the superior vena cava. The catheter was filled with heparin, tunneled, and attached to an adaptor that was positioned in a subcutaneous pocket at the back of the neck, allowing for direct connection of the catheter with the infusion line on the day of experimentation. After 5--6 days of recovery, mice that had lost less than 10% of their preoperative weight were subjected to the clamp study. On the day of experimentation, each animal was deprived of food for 4 h in the morning before placement in the customized clamp-box, allowing for unrestrained, free movements of the mice during the clamp procedure. For clamp studies, D-\[3-3H\]-glucose (PerkinElmer) was administered as a bolus (5 μCi), and then infused continuously (0.05 μCi/min). All solutions infused were prepared with 3% plasma added, obtained from 4 h fasted donor mice. Hyperinsulinemia was achieved by a bolus infusion of insulin (Insuman Rapid; Sanofi Aventis) of 20 μU/g body weight, and thereafter by infusing insulin at a fixed rate of 4 μU/g/min. Blood glucose concentrations were monitored regularly according to a fixed scheme from tail vein bleedings (B-glucose analyzer, Hemocue), and maintained at around 120-140 mg/dl by administering 20% glucose (bela-pharm). An infusate of 2-deoxy-D-\[1-14C\]-glucose (10 μCi; American Radiolabeled Chemicals) was given approximately 120 min before steady state for analysis of tissue specific glucose uptake. Steady state was considered achieved, when a fixed glucose-infusion rate maintained the glucose concentration in blood constant for 30 min. At the end of the experiment, mice were killed by decapitation and liver, perigonadal WAT, BAT, SKM and brain were dissected, snap-frozen in liquid nitrogen and stored at −80°C until further analysis. The \[3-3H\]glucose content in serum during basal conditions and at steady state was measured as described earlier ([@bib44]). The radioactivity of 2-\[1-14C\]-deoxy-d-glucose in plasma was measured directly in a liquid scintillation counter. Lysates of WAT, BAT, SKM and brain were processed through ion-exchange chromatography columns (AGR1-X8 formate resin, 200--400 mesh dry; Poly-Prep Prefilled Chromatography Columns; Bio Rad Laboratories) for the separation of 2-\[1-14C\]-deoxy-d-glucose from 2-\[1-14C\]-deoxy-d-glucose-6-phosphate, 2-\[1-14C\] (2DG6P). The glucose-turnover rate (mg/kg/min) was calculated as described ([@bib44]). Tissue specific glucose uptake in brain, WAT, BAT and SKM was calculated on the basis of the accumulation of 2-\[1-14C\]-deoxy-d-glucose-6-phosphate, 2-\[1-14C\] in the respective tissue and the disappearance rate of 2-\[1-14C\]-deoxy-d-glucose from plasma ([@bib21]) and expressed as nanomol per gram of tissue per minute (nmol/g/min). For evaluation of basal and steady-state clamped insulin serum levels, an ultrasensitive insulin ELISA for determination of human insulin was performed according to manufacturer's instructions (Ultrasensitive ELISA, \#EIA-2337, DRG Instruments GmbH).

### Indirect Calorimetry {#sec6.4.6}

Indirect calorimetry was performed using an open-circuit, indirect calorimetry system (PhenoMaster, TSE systems) as previously described ([@bib58]). In brief, mice were trained for three days before data acquisition to adapt to the food/drink dispenser of the PhenoMaster system. Afterward mice were placed in regular type II cages with sealed lids at room temperature (22°C) and allowed to adapt to the chambers for at least 24 h. Food and water were provided *ad libitum*. All parameters were measured continuously and simultaneously.

### Assessment of Body Composition {#sec6.4.7}

Lean and fat mass were analyzed by computed tomography (CT) in isoflurane-anesthetized mice (Dräger and Piramal Healthcare). For data acquisition on an IVIS Spectrum CT scanner (Caliper LifeScience, USA) we used IVIS LivingImage Software V4.3.1. Quantification of lean and fat mass contents were determined with a modification of the previously described Vinci software package 4.61.0 ([@bib14]) developed at our institution (available at: <https://vinci.sf.mpg.de/>).

### Morris Water Maze {#sec6.4.8}

The Morris Water Maze was used to test spatial memory and to evaluate the working and reference memory functions as previously described ([@bib37]). Mice were assessed at 20-22 weeks of age. The water maze consists of a circular pool (diameter of 120 cm) filled with water (21--22°C). Hidden-platform training (acquisition phase) was conducted with the platform placed in the northeast quadrant 1 cm below the water surface over 9 consecutive days (4 trials/day). Several large visual cues were placed in the room to guide the mice to the hidden platform. Each training trial was finished when the mouse reached the platform (escape latency) or after 60 s. Mice failing to reach the platform were guided onto it. After each training trial, mice remained on the platform for 15 s. To test memory retention, retention trials were performed at day 10 of the test with 16 h-fasted or random-fed mice, respectively, as indicated. In the retention trial, the platform was removed from the pool and mice were allowed to swim for 60 s. The percent of time spent in the target quadrant was recorded. All trials were monitored by a video camera set above the center of the pool and connected to a video tracking system (TSE systems).

### Open Field {#sec6.4.9}

Open-field experiments were performed in an open-field box for mice during the light cycle (TSE Systems, Bad Homburg, Germany) as previously described ([@bib33]). Mice were placed in the open-field box and the time at the center and the border (in %) as well as the distance traveled (in cm) and the speed (cm/s) for each mouse was measured over a period of 45 min using an automated video-based system in an open field (50 cm × 50 cm; VideoMot 2, TSE Systems, Bad Homburg, Germany).

### Rotarod {#sec6.4.10}

In the rotarod test, the mice were placed on a horizontally oriented, 2 cm rotating cylinder (rod). The rotation speed of the rod was accelerating starting at 4 rpm and increasing continuously up to 40 rpm after 300 s. Every animal was placed on the rotating rod four times with 15 min recovery in between each trial. The length of time that the mice stayed on the rotating rod (fall latency) was measured via light beam detection. The average fall latency of four test trials per mouse was calculated.

### Adeno-Associated Virus (AAV)-Injection {#sec6.4.11}

AAV injection in the ARH was performed as described ([@bib26]). In brief, adult, 8-9 week-old GLP-1R^flox/flox^ mice were anesthetized using a ketamine-dexmedetomidine combination and were placed into a stereotaxic apparatus. 0.25 μL of an adeno-associated virus (AAV)5, allowing for Cre-expression (AAV5-hGFAP-iCre; Vector BioLabs) or GFP expression (AAV5-hGAP-eGFP; Vector BioLabs) under the control of the hGFAP promotor in astrocytes was injected into the upper and lower left and right ARH using appropriate coordinates: upper left ARH (anteroposterior (AP): - 1.5 mm, medio-lateral (ML): - 0.3 mm; dorso-ventral (DV): - 5.8 mm), lower left ARH (AP: - 1.5 mm, ML: - 0.3 mm, DV: - 5.9 mm), upper right ARH (AP: - 1.5 mm, ML: + 0.3 mm, DV: - 5.8 mm), lower right ARH (AP: - 1.5 mm, ML: + 0.3 mm, DV: - 5.9 mm).

### Intracerebroventricular Injections {#sec6.4.12}

#### Icv Cannulation {#sec6.4.12.1}

Icv cannulations were performed as described previously ([@bib96]). Briefly, adult mice were anesthetized using a ketamine-dexmedetomidine combination and were placed into a stereotaxic apparatus. 26 gauge cannulas were implanted to the left lateral ventricle using appropriate coordinates (bregma, - 0.2 mm, + 1 mm; dorsal surface, - 2.1 mm). Dental acrylic (Super Bond C&B) was used to secure the cannula to the skull surface. Animals were allowed to recover for at least 1 week prior to experiment. After experiments, stereotaxic implants were anatomically verified.

#### Icv FGF21 Antibody Administration {#sec6.4.12.2}

For icv injection, mice were administered with 2 μl of a neutralizing FGF21 antibody (goat IgG, dissolved in sterile PBS, 2 μg per mouse, \#AF3057, R&D Systems) or control (goat IgG, dissolved in sterile PBS, 2 μg per mouse, \#AB-108-C, R&D Systems) when removing food for the 16 h starvation period ahead of the GTT.

#### Icv GLP-1 Administration {#sec6.4.12.3}

After an overnight fasting period of 16 h, mice were icv injected with 2 μl of either saline (control) or 1 μg of GLP-1 (GLP-1 7-36 amide; \#H-6795, Bachem, Switzerland) 5 min before injecting the \[18F\]FDG and starting the PET scans as outlined below. Icv GLP-1 or saline administration with subsequent PET imaging was conducted in a crossover fashion with a one week wash-out period between the experiments.

### Assessment of Brain Glucose Uptake via ^18^F-FDG PET Scans {#sec6.4.13}

PET imaging was performed using an Inveon preclinical PET/CT system (Siemens). Random-fed or 16 h-fasted mice were anesthetized with 2% isoflurane in 65%/35% nitrous oxide/oxygen gas and positioned on a dedicated mouse carrier (MEDRES, Germany) carrying two mice. Body temperature was maintained at 37.0 ± 0.5°C by a thermostatically controlled water heating system. For injection of the radiotracer, a catheter consisting of a 30 G cannula connected to a polythene tubing (ID = 0.28 mm) was inserted into the tail vein and fixated by a drop of glue. After starting the PET scan, 7-8 MBq of \[18F\]FDG in 50-100 μL saline were injected per mouse. Emission data were acquired for 45 min. Thereafter, animals were automatically moved into the CT gantry and a CT scan was performed (180 projections/360°, 200 ms, 80 kV, 500 μA). The CT data were used for attenuation correction of the PET data and the CT image of the scull was used for image co-registration. Plasma glucose levels were determined from a tail vein blood sample using a standard glucometer (Bayer) after removing the tail vein catheters. PET data were histogrammed in time frames of 12x30 s, 3x60 s, 3x120 s, 7x240 s, Fourier rebinned, and images were reconstructed using the MAPSP algorithm provided by the manufacturer. For co-registration the imaging analysis software Vinci was used ([@bib14]). Images were co-registered to a 3D mouse brain atlas constructed from the 2D mouse brain atlas published by [@bib68].

#### Kinetic Modeling {#sec6.4.13.1}

An image-derived input function was extracted from the PET data of the aorta, which could be identified in the image of the first three to five time frames of each animal. Input function data were corrected for partial volume effect by assuming a standardized volume fraction of 0.6 ([@bib31]). Parametric images of the \[18F\]FDG kinetic constants K1, k2, k3, and k4 were determined by a voxel-by-voxel (voxel size = 0.4 mm x 0.4 mm x 0.8 mm) fitting of data to a two- tissue-compartment kinetic model. K1 is the constant for transport from blood to tissue, k2 for transport from tissue to blood, k3 the constant for phosphorylation of \[18F\]FDG to \[18F\]FDG-6-phosphate, and k4 the constant for dephosphorylation. Additional parametric images of the cerebral metabolic rate of glucose and the extracellular glucose level were calculated. The cerebral metabolic rate of glucose was calculated taking into account the different efficiencies of \[18F\]FDG and glucose, a method that is insensitive to changes of the lumped constant ([@bib7]):

CP indicates the plasma glucose level. CE/CP is the ratio of extracellular to plasma glucose and was used to quantify glucose uptake.

#### Statistics {#sec6.4.13.2}

Statistical testing was performed by application of a voxel-wise t test between groups. 3D maps of p values allow for identification of regions with significant differences in the parameters. From these regions we defined volumes of interest (VOIs) and performed additional statistical testing for these VOIs. For presentation only, 3D maps of p values were re-calculated on a 0.1 mm x 0.1 mm x 0.1 mm grid from the original dataset using trilinear interpolation.

### Analysis of Gene Expression {#sec6.4.14}

RNA was isolated from primary astrocytes using the RNeasy Kit (QIAGEN) according to manufacturer's suggestions. RNA was reversely transcribed with High Capacity cDNA RT Kit and amplified using TaqMan Universal PCR-Master Mix (Applied Biosystems). All samples were treated with DNase. Relative expression of target mRNAs was adjusted for total RNA content by *Hprt* (Mm01545399_m1). Inventoried Taqman probes were used: *ATF4* Mm00515324_m1, *ATF5* Mm04179654_m1, *Hspa5* (BIP) Mm00517691_m1, *Ddit3* (CHOP) Mm00492097_m1, *Ppara* (Pparα) Mm00440939_m1, *FGF21* (Mm00840165_g1), *mouse GLP-1R* (Mm00445292_m1). To assess *GLP-1R* knock-out efficiency in primary astrocytes the following designed probes were used: Flag primer 5′913: GGACTACAAGGATGACGACGAC, 3′ 3580-152: CCCAAGGCACACAAAAAACC, mUTRprobe: 5′ FAM TGGCCATCCCAGGTGGGAGAGATCCT 3′TAMRA. Calculations were performed by a comparative method (2^−ΔΔCT^). Quantitative PCR was performed on an AB-QuantStudio 7 Flex (Applied Biosystems).

### Analysis of Mitochondrial DNA {#sec6.4.15}

Mitochondrial DNA present per nuclear genome was determined using the following primer pairs: mitochondrial Nd2: fw: 5′- AGGGATCCCACTGCACATAG-3′; rev: 5′- CTCCTCATGCCCCTATGAAA-3′; mitochondrial D-Loop: fw: 5′- GGTTCTTACTTCAGGGCCATCA-3′, rev: 5′-GATTAGACCCGATACCATCGAGAT-3′; nuclear Nduv: fw: 5′- CTTCCCCACTGGCCTCAAG-3′; rev: 5′- CCAAAACCCAGTGATCCAGC-3′. Relative mitochondrial DNA content was calculated relative to nuclear DNA content based on the 2 × 2^ΔCT^ method ([@bib77]). Quantitative PCR was performed on an AB-QuantStudio 7 Flex (Applied Biosystems).

### Western Blotting {#sec6.4.16}

Western blot analysis was conducted as previously described ([@bib96]). In brief, membranes were blocked with 10% WB-blocking reagent (Roche, Switzerland) in Tris-buffered saline containing 0.1% Tween-20 (TBS-T), and incubated with primary antibodies, made up in TBS-T (0.1% Tween-20) and 5% Western Blotting-Reagent, at 4°C overnight. The following primary antibodies and dilutions were used: anti-GLP-1R (1:1000, \#NBP1-97308, Novus Biologicals), anti-Akt (\#4686, Cell Signaling), anti-p-Akt(S473) (\#4060, Cell Signaling), anti-NDUFA9 (1:1000, \#459100, Invitrogen), anti-NDUFB8 (1:1000, \#459210, Invitrogen), anti-Complex II 70 kDa Fp Subunit (1:1000, \#459200, Invitrogen), anti-UQCRC1 (1:1000, \#459140, Invitrogen), anti-Complex IV (1:1000, \#459110, Invitrogen), anti-ATP synthase subunit β (1:1000, \#21351, Invitrogen), anti-p-Ser-226-GLUT-1 (\#ABN991, Merck Millipore), anti-GLUT-1 (\#07-1401, Merck Millipore), anti-FGF21 (\#AF3057, R&D Systems) and, as loading control: anti-calnexin (1:4000, \#208880, Merck Milipore). Quantification of chemiluminescent signals was performed with the ImageJ (Fiji)-software package ([@bib87]).

### Astrocyte-Specific GLP-1R Deletion *In Vitro* {#sec6.4.17}

Hypothalamic explants were isolated from GLP-1R^flox/flox^ male mice at postnatal day 1-3. After a total of 15 days in culture, allowing for astrocyte GFAP expression ([@bib83]), cells were incubated with AAV(5)-GFAP(2.2)-eGFP (control) or AAV(5)-GFAP(2.2)-iCre (GLP-1R KO) from Vector BioLabs in DMEM high glucose, GlutaMAX supplemented with heat-inactivated 10% FBS and 1% penicillin/streptomycin for 8 h in 5% CO2 at 37°C. To enhance transduction efficacy, 0.25% of AdenoBOOST (\#SB-P-AV-101-02, Sirion Biotech) were added. After extensive washing in HBSS, cells were incubated in complete medium (DMEM high glucose, GlutaMAX with 10% heat-inactivated FBS and 1% penicillin/streptomycin) for additional 3 days before subjecting cells to final experiments.

### Assessment of Oxygen Consumption Rate and Extracellular Acidification Rate in Primary Hypothalamic Astrocytes {#sec6.4.18}

Oxygen consumption rate (OCR) in GLP-1R-deficient or control primary hypothalamic astrocytes was measured using the XFe96 Extracellular Flux Analyzer (Seahorse, Agilent Technologies) in XF Base Medium (Agilent) supplemented with 1 mM glutamine under basal conditions and in response to 10 mM glucose (\#G8769, Sigma), 1.0 μM oligomycin, 1.0 μM fluoro-carbonyl cyanide phenylhydrazone (FCCP) and 1.0 μM Rotenone/Antimycin A (all XF Cell Mito Stress Test Kit \# 101706-100, Agilent Technologies) according to manufacturer's instructions.

Extracellular acidification rate (ECAR) in GLP-1R-deficient or control primary hypothalamic astrocytes was also measured using the XFe96 Extracellular Flux Analyzer (Seahorse, Agilent Technologies) as previously described ([@bib60]). Therefore, cells were glucose-starved in DMEM (\#11966025, GIBCO, ThermoFisher Scientific) at 2 mM glucose (\#G8769, Sigma) and 1% penicillin/streptomycin for 4 h. ECAR was then assessed in XF Base Medium (Agilent) supplemented with 1 mM glutamine and 2 mM or 25 mM glucose under basal conditions and in response to 1.0 μM oligomycin, 1.0 μM FCCP and 1.0 μM Rotenone/Antimycin A (all XF Cell Mito Stress Test Kit \# 101706-100, Agilent Technologies) according to manufacturer's instructions.

To assess GLP-1 effects on OCR in the presence of glucose, primary hypothalamic astrocytes were starved for 16 h in substrate-limited DMEM (\#11966-025, Thermo Fisher Scientific) containing 4 mM glutamine, 0.5 mM glucose (Sigma), 0.5 mM L-Carnitine hydrochloride (Sigma), 1% heat inactivated FBS, and 1% penicillin/streptomycin. OCR was then measured in XF Base Medium (Agilent) supplemented with 1 mM glutamine in the presence or absence of 40 μM etomoxir (\#E1905, Sigma, preincubation 15 min) and upon acute addition of 100 nM GLP-1 (GLP-1 7-36 amide; \#H-6795, Bachem, Switzerland) or 0.1% DMSO (Sigma) just before starting the measurement under basal conditions and in response to 10 mM glucose (\#G8769, Sigma), 1.0 μM oligomycin, 1.0 μM FCCP and 1.0 μM Rotenone/Antimycin A (all XF Cell Mito Stress Test Kit \# 101706-100, Agilent Technologies) according to manufacturer's instructions. Beta oxidation was assessed as OCR max without etomoxir -- OCR max with etomoxir for the respective treatment group.

To assess GLP-1-induced exogenous and endogenous fatty acid oxidation, primary hypothalamic astrocytes were starved for 16 h in substrate-limited DMEM (\#11966-025, Thermo Fisher Scientific) containing 4 mM glutamine, 0.5 mM glucose (Sigma), 0.5 mM L-Carnitine hydrochloride (Sigma), 1% heat inactivated FBS, and 1% penicillin/streptomycin. OCR was then measured in FAO Assay Medium (Krebs-Ringer-Buffer (111 mM NaCl, 4.7 mM KCl, 1.25 mM CaCl2, 2 mM MgSO4, 1.2 mM NaH2PO4) supplemented with 2.5 mM glucose, 0.5 mM L-Carnitine hydrochloride (Sigma), and 5 mM HEPES (Sigma), adjusted to pH 7.4) in the presence or absence of 40 μM etomoxir (Sigma, preincubation 15 min) and upon addition of 167 μM XF Palmitate-BSA or 28 μM XF BSA Control (\#102720-100, Agilent Technologies) in response to 1.0 μM oligomycin, 1.0 μM FCCP and 1.0 μM Rotenone/Antimycin A (all XF Cell Mito Stress Test Kit \# 101706-100, Agilent Technologies) according to manufacturer's instructions. For the assessment of GLP-1-induced exogenous and endogenous fatty acid oxidation 100 nM GLP-1 (GLP-1 7-36 amide; \#H-6795, Bachem, Switzerland) or 0.1% DMSO (Sigma) were applied to the cells just right before the addition of palmitate or BSA, respectively.

Beta oxidation was assessed as OCR max without etomoxir -- OCR max with etomoxir for the respective treatment group as indicated.

### Assessment of Glucose Uptake in Primary Hypothalamic Astrocytes {#sec6.4.19}

Cellular glucose uptake was assessed using a fluorescent 2-\[N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino\]-2-deoxy-d-glucose (2-NBDG) assay (\#Cay-600470, Cayman Chemical, USA) as previously described ([@bib37], [@bib109]). In brief, GLP-1R-deficient or control primary hypothalamic astrocytes were washed twice with HBSS and were then incubated in DMEM (\#11966025, GIBCO, ThermoFisher Scientific) with 2 mM glucose (\#G8769, Sigma) and 1% penicillin/streptomycin for 4 h. Cells were then washed again twice with HBSS before they were incubated for 30 min in DMEM with 100 mM 2-NDBG. Following, cellular glucose uptake was measured according to manufacturer's instructions. Where indicated, cells were either pre-incubated with the GLUT-1 specific inhibitor WZB117 (10 μM, dissolved in DMSO, \#SML0621, Sigma Aldrich) or control (DMSO 0.1%) in DMEM (\#11966025, GIBCO, ThermoFisher Scientific) with 2 mM glucose (\#G8769, Sigma) and 1% penicillin/streptomycin for 4 h prior to incubation with 100 mM 2-NDBG for 30 min as indicated above.

To assess GLP-1-induced glucose uptake, primary hypothalamic astrocytes from C57Bl6/N mice were starved for 16 h in substrate-limited DMEM (\#11966-025, Thermo Fisher Scientific) containing 4 mM glutamine, 0.5 mM glucose (Sigma), 1% heat-inactivated FBS, and 1% penicillin/streptomycin. Cells were then washed twice with HBSS before they were incubated for 30 min in DMEM and 100 mM 2-NDBG with 100 nM GLP-1 (GLP-1 7-36 amide; \#H-6795, Bachem, Switzerland) or 0.1% DMSO (Sigma), respectively. Following, cellular glucose uptake was measured according to manufacturer's instructions.

### Anion-Exchange Chromatography Mass Spectrometry (AEX-MS) for analysis of glycolysis metabolites {#sec6.4.20}

After a 4 h incubation period in substrate-limited DMEM (\#11966-025, Thermo Fisher Scientific) containing 4 mM glutamine, 2 mM glucose (Sigma), and 1% penicillin/streptomycin (Invitrogen), GLP-1R-deficient or control primary hypothalamic astrocytes were exposed to high (25 mM) or low (2 mM) glucose (\#G8769, Sigma) for 1 h. Afterward, cells were washed twice with wash solution (75 mM ammonium carbonate in water, pH 7.4). Then, cells were incubated for 10 min in cell extraction solvent (40:40:20 acetonitrile:methanol:water) on dry ice to quench cellular metabolism. Afterward, cells were harvested, pelleted by centrifugation and stored at −80°C until further analysis.

The dried pellet of the metabolite extract was re-suspended in 180 μL of H~2~O (LC-MS Optima-Grade, Thermo Scientific) and analyzed using a Dionex ionchromatogrypy system (ICS 5000, Thermo Scientific). The applied protocol was adopted from ([@bib88]). In brief: 10 μL of polar metabolite extract were injected in full loop mode using an overfill factor of 3, onto a Dionex IonPac AS11-HC column (2 mm × 250 mm, 4 μm particle size, Thermo Scientific) equipped with a Dionex IonPac AG11-HC guard column (2 mm × 50 mm, 4 μm, Thermo Scientific). The column temperature was held at 30°C, while the auto sampler was set tot 6°C. A potassium hydroxide gradient was generated by the eluent generator using a potassium hydroxide cartridge that was supplied with deionized water. The metabolite separation was carried at a flow rate of 380 μL/min, applying the following gradient. 0-5 min, 10−25 mM KOH; 5-21 min, 25−35 mM KOH; 21-25 min, 35-100 mM KOH, 25-28 min, 100 mM KOH, 28-32 min, 10-100 mM KOH. The column was re-equilibrated at 10 mM for 6 min.

The eluting metabolites were detected in negative ion mode using ESI MRM (multi reaction monitoring) on a Xevo TQ (Waters) triple quadrupole mass spectrometer applying the following settings: capillary voltage 1.5 kV, desolvation temp. 550°C, desolvation gas flow 800 L/h, collision cell gas flow 0.15 mL/min. All peaks were validated using two MRM transitions one for quantification of the compound, while the second ion was used for qualification of the identity of the compound. The following MRM transitions were used for relative compound quantification: Glucose-6-phosphate m/z precursor mass (M-H^+^) 259, fragment mass (M-H^+^) m/z 79 using a cone voltage of 20 V and a collision energy of 24 V. Fructose-6-phosphate m/z precursor mass (M-H^+^) 259, fragment mass (M-H^+^) m/z 79 using a cone voltage of 20 V and a collision energy of 28 V. Fructose-1,6-bisphosphate m/z precursor mass (M-H^+^) 339, fragment mass (M-H^+^) m/z 97 using a cone voltage of 26 V and a collision energy of 22 V. 3-phosphoglyceric acid m/z precursor mass (M-H^+^) 187, fragment mass (M-H^+^) m/z 97 using a cone voltage of 20 V and a collision energy of 12 V. Phosphoenolpyruvate m/z precursor mass (M-H^+^) 177, fragment mass (M-H^+^) m/z 79 using a cone voltage of 14 V and a collision energy of 10 V. Lactate m/z precursor mass (M-H^+^) 89, fragment mass (M-H^+^) m/z 43 using a cone voltage of 20 V and a collision energy of 6 V. Data analysis and peak integration was performed using the TargetLynx Software (Waters).

### Measurement of L-lactate Secretion {#sec6.4.21}

After a 4 h incubation period in substrate-limited DMEM (\#11966-025, Thermo Fisher Scientific) containing 4 mM glutamine, 2 mM glucose (\#G8769, Sigma), and 1% penicillin/streptomycin, GLP-1R-deficient or control primary hypothalamic astrocytes were exposed to high (25 mM) or low (2 mM) glucose for 1 h. Afterward, L-lactate was assessed in the cell supernatant using an L-lactate Assay kit (Abcam, \#ab65331) according to the manufacturer's instructions.

### Electrophysiology Methods {#sec6.4.22}

Perforated patch-clamp experiments were performed on dopaminergic neurons in the SNc from overnight fasted male GLP-1R^ΔGFAP^ and control mice. To validate the location of recorded neurons they were post hoc double staining for tyrosine hydroxylase (TH) and biocytin as previously described in [@bib33].

#### Brain Slice Preparation {#sec6.4.22.1}

Animals were anesthetized with isoflurane (\#B506; AbbVie Deutschland GmbH and Co KG) and subsequently decapitated. The brain was rapidly removed and a block of tissue containing the mesencephalon was immediately dissected. Coronal slices (270 - 300 μm) containing the SN were cut with a vibration microtome (\#VT1200s, Leica) in cold (4°C), carbogenated (95% O~2~ and 5% CO~2~), glycerol-based modified artificial cerebrospinal fluid (GACSF). GACSF contained (in mM): 240 Glycerol, 2.5 KCl, 2 MgCl~2~, 2 CaCl~2~, 1.2 NaH~2~PO~4~, 10 HEPES, 21 NaHCO~3~, 5 glucose adjusted to pH 7.2 (with NaOH). After cutting brain slices were immediately transferred into carbogenated artificial cerebrospinal fluid (ACSF). ACSF contained (in mM): 125 NaCl, 2.5 KCl, 2 MgCl~2~, 2 CaCl~2~, 1.2 NaH~2~PO~4~, 21 NaHCO~3~, 10 HEPES, and 5 glucose adjusted to pH 7.2 (with NaOH). They were kept for 20 min in a 35°C recovery bath and then stored at room temperature (24°C) for at least 30 min before recordings were taken. For the experiments, brain slices were transferred to a recording chamber (\~1.5 mL volume) and continuously superfused with carbogenated ACSF at a flow rate of \~2 ml·min^-1^. Experiments were performed at \~32°C.

#### Patch Clamp Recordings {#sec6.4.22.2}

Recordings were performed with an EPC10 amplifier (HEKA) controlled with the software PatchMaster (version 2.32; HEKA). In parallel data were sampled at 25 or 50 kHz with a CED 1401 using Spike2 (version 7) (both Cambridge Electronic Design) and low-pass filtered at 2 kHz with a four-pole Bessel filter. The liquid junction potential between intracellular and extracellular solution was compensated (14.6 mV; calculated with Patcher's Power Tools plug-in for Igor Pro 6 (Wavemetrics).

Perforated patch recordings were performed using protocols modified from [@bib34] and [@bib2]. Electrodes with tip resistances between 3 and 5 MΩ were fashioned from borosilicate glass (0.86 mm inner diameter; 1.5 mm outer diameter; GB150- 8P; Science Products) with a vertical pipette puller (Narishige). Patch recordings were performed with ATP and GTP free pipette solution containing (in mM): 140 K-gluconate, 10 KCl, 10 HEPES, 0.1 EGTA, 2 MgCl~2~ and adjusted to pH 7.2 (with KOH). ATP and GTP were omitted from the intracellular solution to prevent uncontrolled permeabilization of the cell membrane ([@bib53]). The patch pipette was tip filled with internal solution and back filled with internal solution containing additional 1% biocytin (\#B4261, Sigma-Aldrich) and 0.02% tetraethylrhodamine-dextran (\#D3308, Invitrogen) and the ionophore amphotericin (\~200-250 μg·ml^-1^; \#G4888; Sigma-Aldrich). Amphotericin was dissolved in dimethyl sulfoxide (final concentration: 0.1 - 0.3%; DMSO; \#D8418, Sigma-Aldrich) ([@bib47]); and was added to the modified pipette solution shortly before use. The used DMSO concentration had no obvious effect on the investigated neurons. During recording the access resistance (*R*~a~) was constantly monitored and experiments were started once the action potential amplitude was stable and the *R*~a~ was \< 80 MΩ (\~20 -- 40 min). A change to the whole-cell configuration was repeatedly checked over the duration of an experiment. If the *R*~a~ suddenly changed and tetraethylrhodamine-dextran rapidly diffused into the neuron the experiment was excluded from analysis. To block GABAergic and glutamatergic synaptic input the ACSF contained 10^−4^ M picrotoxin (\#P1675; Sigma-Aldrich), 5 × 10^−5^ M D-AP5; \#A5282; Sigma-Aldrich), and 10^−5^ M CNQX (\#C127; Sigma-Aldrich).

After completion of a recording, the patch was converted to the whole-cell configuration to allow biocytin to diffuse into the cell for \~30 s. Brain slices were fixed in Roti-Histofix (\#P0873, Carl Roth) overnight at 4°C and rinsed with PBS buffer. Slices were incubated in PBS with 2% Triton X (SERVA) (PBS-T) and 10% normal goat serum (30 min). Afterwards, brain slices were incubated in chicken anti-TH (1:500, \#ab76442, Abcam) in PBS-T with 10% normal goat serum (\#S-1000, Vector Laboratories) overnight at RT. After primary incubation brain slices were rinsed with PBS 3x for 15 min. followed by an incubation for 2 h in PBS containing the following: Alexa 633--conjugated streptavidin (1:500, \#S21375, Invitrogen), dylight 488 anti-chicken IgG (1:500, \#ab96947, Abcam) and 0.5% Triton X. Lastly, brain slices were rinsed in PBS 5x for 10 min, dehydrated with ethanol, cleared with xylol and mounted in Permount (Fisher Scientific). Fluorescence images were captured with a confocal microscope (SP8, Leica) mounted with PL APO 10x/0.40 and PL APO 63/1.2 objectives.

#### Data Analysis {#sec6.4.22.3}

Average frequencies of neurons were calculated from 5 min of spontaneous activity. Coefficients of variation (CV) were calculated from 5 min of spontaneous activity. Sample differences were tested for statistical significance with GraphPad Prism 6. For the spontaneous activity and the CV an unpaired t test was performed. Statistical significances are indicated as p ≤ 0.05 (^∗^). In boxplots, horizontal lines indicate the median of the data, + sign indicates the mean of the data; boxes indicate the 25th and 75th percentile and whiskers were calculated according to the Tukey method.

Data analysis and graphical illustrations were performed using GraphPad Prism 6 (GraphPad Software), Microsoft Excel (Microsoft Corp.), Adobe Illustrator (Adobe Systems Software), Spike2 (Electronic Design) and Fiji (<https://imagej.net/Fiji>) software.

### Histology {#sec6.4.23}

#### IP administration of liraglutide^594^ and analysis of liraglutide^594^--labeled GFAP-expressing astrocytes in the ARH {#sec6.4.23.1}

To assess functional GLP-1R expression in GFAP-expressing astrocytes in the ARH of GLP-1R^ΔGFAP^ and control mice or in C57Bl6/N and conventional GLP-1R-deficient (GLP-1R^Δ/Δ^) mice, random-fed mice were injected ip with liraglutide^594^ (120 pmol/g body weight) at 8 am and afterward food was removed. 5 h after injection of liraglutide^594^ animals were deeply anesthetized and perfused transcardially with 0.9% saline followed by 4% paraformaldehyde (PFA) as previously described ([@bib96], [@bib97]). Brains were removed, postfixed overnight in 4% PFA and then transferred to 20% sucrose in 0.1 M PBS (pH 7.4) overnight. Perfused brains were frozen at −80°C and afterward 30 μm thick sections were cut on a cryostat. Every fourth section throughout the ARH was processed for GFAP immunohistochemistry and liraglutide^594^ detection. To ensure comparable immunostaining, sections were processed simultaneously under identical conditions. All incubations were done at room temperature under light-protected conditions unless otherwise stated. Briefly, for GFAP immunohistochemistry, sections were allowed to dry before they were incubated with 4% PFA for 10 min. Thereafter, slides were washed with PBS twice for 10 min before they were incubated with 0,3% Glycine, 0.1 M PBS for 10 min. Then, slides were washed with PBS for 10 min, treated with 0,03% SDS in 0.1 M PBS for 10 min and blocked using 3% donkey serum (diluted in 0.25% Triton X, 0.1 M PBS) for 60 min. Following, slides were incubated with anti-GFAP antibody (\#7260, Abcam,1:1000, diluted in Signal Stain, Cell Signaling) for 16 h at 4°C. Slides were then washed 3 x with PBS; 0.1% Triton X for 10 min and incubated with the secondary antibody (donkey-anti-rabbit, Alexa 488 (\#A21206), 1:500 diluted in 0.1 M PBS, 0.25 Triton X) for 60 min. After a final washing 3 x with 0.1 M PBS, 0.1% Triton X for 10 min, slides were mounted with DAPI-containing vectashield (Vector Laboratories).

Images were acquired using a confocal Leica TCS SP-8-X microscope equipped with a 40x objective. To ensure similar imaging conditions for all pictures of all brains, exact same microscope set-up (including objective, zoom, laser power, gain) was used to acquire all pictures within the same experiment. All images were taken with a pinhole of 1 airy unit (AU). For representative images, maximum intensity projections were made in FIJI (NIH) and images were equally adjusted for brightness and contrast.

#### Quantitative Analysis of liraglutide^594^ Positive GFAP-astrocytes and GFAP-negative Cells {#sec6.4.23.2}

The total number of GFAP-positive astrocytes as well as the number of liraglutide^594^-positive astrocytes and of liraglutide^594^-positive,GFAP-negative cells was quantified unilaterally in images from every fourth section of every animal throughout the ARH using ImageJ analysis software (NIH) as previously reported ([@bib96], [@bib97]). The average percentage of liraglutide^594^-positive astrocytes counted in 5-6 hemisections from the ARH of 4 GLP-1R^ΔGFAP^ and 4 control mice was used for statistical comparison.

#### Immunohistochemistry for liraglutide^594^ and GFP Detection in GFAP-expressing Astrocytes in the ARH {#sec6.4.23.3}

To assess expression of GLP-1R and GFP in GFAP-expressing astrocytes in the ARH of GLP-1R^flox/flox^ which had received an ARH injection of AAV5-hGFAP-iCre or AAV5-hGFAP-eGFP, random-fed mice were deeply anesthetized and perfused transcardially with 0.9% saline followed by 4% PFA as previously described ([@bib96], [@bib97]). Brains were removed, postfixed overnight in 4% PFA and then transferred to 20% sucrose in 0.1 M PBS (pH 7.4) overnight. Perfused brains were frozen at −80°C and afterward 30 μm thick sections were cut on a cryostat. Every fourth section throughout the ARH was processed for liraglutide^594^, GFP and GFAP immunohistochemistry. To ensure comparable immunostaining, sections were processed simultaneously under identical conditions. All incubations were done at room temperature under light-protected conditions unless otherwise stated. Briefly, sections were allowed to dry before they were incubated with 4% PFA for 5 min. Afterward, slides were washed with PBS twice for 10 min before they were incubated with 0,3% Glycine, 0.1 M PBS for 10 min. Then, slides were washed with PBS for 10 min, treated with 0,03% SDS in 0.1 M PBS for 10 min and blocked using 3% donkey/3% goat serum (diluted in 0.25% Triton X, 0.1 M PBS) for 60 min. Following, slides were incubated with anti-GFP antibody (\#13970, Abcam,1:1000, diluted in Signal Stain, Cell Signaling) and anti-GFAP antibody (\#7260, Abcam,1:1000, diluted in Signal Stain, Cell Signaling) for 16 h at 4°C. Slides were then washed 3 x with PBS for 10 min and incubated with the secondary antibodies (goat-anti-chicken, FITC 1:500 diluted in 0.1 M PBS, 0.25% Triton X and donkey-anti-rabbit, Alexa 647, 1:500 diluted in 0.1 M PBS, 0.25% Triton X, respectively) for 60 min. Slides were then washed 3 × 10 min with 0.1% Triton X, 0.1 M PBS, afterward quickly dipped into PFA 4% and washed with PBS before incubation with 1X Roti-Block (Carl Roth GmbH, Germany) for 60 min. Afterward, slides were incubated with liraglutide^594^ (120 nM, stock dissolved in buffer (50 mM phosphate, 70 mM NaCl, 0.007% Tween20; pH 8.2) further diluted in Signal Stain) for 16 h at 4°C. After a final washing 3 x with 0.1 M PBS, 0.1% Triton X for 10 min, slides were mounted with DAPI-containing vectashield (Vector Laboratories). Images were acquired using a confocal Leica TCS SP-8-X microscope equipped with a 40x objective. To ensure similar imaging conditions for all pictures of all brains, exact same microscope set-up (including objective, zoom, laser power, gain) was used to acquire all pictures within the same experiment. All images were taken with a pinhole of 1 airy unit (AU). For representative images, maximum intensity projections were made in FIJI (NIH) and images were equally adjusted for brightness and contrast.

#### GFAP Immunocytochemistry in Primary Astrocytes *In Vitro* {#sec6.4.23.4}

To assess GFAP expression in primary hypothalamic astrocytes *in vitro*, primary astrocytes were seeded on 8-well removable chamber slides (\#80841, Ibidi) which were treated with Poly-L-Lysine (\#P4707, Sigma-Aldrich) for 30 min at room temperature before seeding the cells. After 3 days cells were treated directly with 4% PFA 10 min, washed with PBS for 10 min and incubate with 0,3% Glycine, 0.1 M PBS for 10 min. Afterward, cells were washed with PBS for 5 min, treated with 0,03% SDS in 0.1 M PBS for 10 min and blocked using 3% donkey serum (diluted in 0.25% Triton X, 0.1 M PBS) for 60 min. Then, cells were incubated with anti-GFAP antibody (\#7260, Abcam,1:1000, diluted in Signal Stain, Cell Signaling) for 16 h at 4°C. Cells were washed with PBS for 10 min and secondary antibody (donkey-anti-rabbit, Alexa 488, 1:500 diluted in 0.1 M PBS, 0.25% Triton X) was added for 60 min. After a washing step for 10 min using 0.1 M PBS, 0.1% Triton X, cells were mounted with DAPI-containing vectashield (Vector Laboratories). Images were acquired using a confocal Leica TCS SP-8-X microscope equipped with a 40x objective. To ensure similar imaging conditions for all pictures of all slides, exact same microscope set-up (including objective, zoom, laser power, gain) was used to acquire all pictures within the same experiment. All images were taken with a pinhole of 1 airy unit (AU). For representative images, maximum intensity projections were made in FIJI (NIH) and images were equally adjusted for brightness and contrast.

#### TOM20 Immunocytochemistry in Primary Astrocytes *In Vitro* {#sec6.4.23.5}

To assess mitochondrial morphology in primary astrocytes *in vitro*, primary astrocytes from 3 different pups from 3 different mothers were seeded on 8-well removable chamber slides (\#80841, Ibidi) and after 5 days cells were incubated with AAV(5)-GFAP(2.2)-GFP; control or AAV(5)-GFAP(2.2)-iCre; GLP-1R KO as described above. Afterward, cells were incubated in DMEM high glucose, GlutaMAX with 10% heat-inactivated FBS and 1% penicillin/streptomycin for additional 3 days. Then cells were carefully washed twice with HBSS and incubated in DMEM medium containing 2 mM glucose (\#G8769, Sigma Aldrich) and 1% penicillin/streptomycin for 4 h. Cells were then either subjected to DMEM with 2 mM or 25 mM glucose for 20 min.

Afterward, cells were washed carefully twice with PBS before and after fixation with 4% PFA for 20 min and then permeabilized in 0.1 M PBS, 0.1% Triton X for 10 min. After washing with PBS, cells were blocked using 10% FBS-PBS for 60 min and then incubated with anti-TOM20 antibody (\#sc-11415, Cell Signaling, 1:1000, diluted in 5% FBS-PBS) for 16 h at 4°C. Cells were washed with PBS for 10 min and secondary antibody (goat-anti-rabbit, Alexa 488, \#A11008, 1:500 diluted in 5% FBS-PBS) was added for 60 min. After a washing step for 10 min with PBS, cells were mounted with DAPI-containing vectashield (Vector Laboratories). Images were acquired using a confocal Leica TCS SP-8-X microscope equipped with a 40x objective. To ensure comparable imaging conditions for all pictures of all slides, exact same microscope set-up (including objective, zoom, laser power, gain) was used to acquire all pictures within the same experiment. All images were taken with a pinhole of 1 airy unit (AU). For representative images, maximum intensity projections were made in FIJI (NIH) and images were equally adjusted for brightness and contrast.

#### Quantitative Analysis of Mitochondrial Morphology in Primary Astrocytes *In Vitro* {#sec6.4.23.6}

Astrocyte cultures form 3 different pups from 3 different mothers were used. 2 slides per condition and 16 pictures per slide were imaged and analyzed in a blinded, pre-defined manner using ImageJ analysis software (NIH). For quantification, only cells that depicted a corresponding DAPI-positive nucleus were included in the analysis and total cell number per slide was recorded. Mitochondrial morphology of each cell was defined as "fragmented," "intermediate" or "fused." The percentage of fragmented, intermediate and fused cells per slide was then averaged for each condition per pup. Finally, the average percentage of fragmented, intermediate and fused cells per condition of each pup (n = 3) was used for statistical comparison.

#### Fluorescent *In Situ* Hybridization of FGF21 Combined with Immunohistochemistry of GFAP {#sec6.4.23.7}

Mice were deeply anesthetized and perfused transcardially with 0.9% saline followed by 4% PFA. Brains were removed, postfixed overnight in 4% PFA and then transferred to 20% sucrose in 0.1 M PBS (pH 7.4) overnight. Perfused brains were frozen and afterward 30 μm thick sections were cut on a cryostat. Fluorescent *in situ* hybridization for the detection of the *FGF21* was performed using RNAscope (ACD; Advanced Cell Diagnostics, Hayward, CA). The probe used to detect *FGF21* was targeting the region 5 -- 904 of the *FGF21* transcript (Acc. No: [NM_020013.4](ncbi-n:NM_020013.4){#intref0230}; ACD). Negative and positive control probes recognizing dihydrodipicolinate reductase, DapB (a bacterial transcript) and cyclophilin and PolR2A, respectively, were processed in parallel with the target probes to ensure tissue RNA integrity and optimal assay performance. Thereby a negative control section of the hypothalamus from every animal was run in parallel. All pretreatment reagents, detection kit and wash buffer were purchased from ACD. All incubation steps were performed at 40°C using a humidified chamber and a HybEz oven (ACD) unless indicated otherwise. On the day before the assay, sections were defrosted and briefly dipped in diethyl-pyrocarbonate (DEPC) treated Millipore water and dried at 60°C overnight. On the day of the assay, slides were first submerged in H2O2 for 10 min, then steamed at 100°C in Target Retrieval (ACD) for 15 min, followed by two brief rinses in DEPC water. The slides were then quickly dehydrated in 100% ethanol and allowed to air dry overnight. The following day, sections were incubated with Protease III (ACD) for 7 min. The subsequent steps, i.e., hybridization of the probe, the amplification steps and detection of the probe, were performed according to the online protocol for RNAscope Enhancer Fluorescent Kit v2 (\#323100, ACD). In brief, the procedure included the following steps: The *FGF21* probe (channel 1) was hybridized to the sections for 2 h, followed by 2x2 min washes in wash buffer (ACD), incubation with Amp1 for 30 min, two washes, Amp2 for 30 min, two washes and finally Amp3 for 15 min followed by two washes. Sections were then incubated in HRP-C1 solution for 15 min followed by two washes and then incubated in channel 1-probe associated TSA Plus Cyanine 5 (1:750, \#NEL745E001KT, Perkin Elmer) for 30 min followed by two washes and a subsequent incubation in HRP blocker solution for 15 min followed by two washes. Sections were then subjected to GFAP staining via immunohistochemistry. Therefore, slides were blocked using 3% donkey serum (diluted in 0.25% TritonX, 0.1 M PBS) for 60 min. Following, slides were incubated with anti-GFAP antibody (\#7260, Abcam,1:800, diluted in Signal Stain, Cell Signaling) for 16 h at 4°C. Slides were then washed 3 x with PBS for 10 min and incubated with the secondary antibody (donkey-anti-rabbit, Alexa 488 (\#A21206), 1:500 diluted in 0.1 M PBS, 0.25% Triton X) for 60 min. After a final washing 3 x with 0.1 M PBS, 0.1% Triton X for 10 min, slides were mounted with DAPI-containing vectashield (Vector Laboratories).

Images were acquired using a confocal Leica TCS SP-8-X microscope equipped with a 40x objective for acquisition of *FGF21* and GFAP staining. To ensure similar imaging conditions for all pictures of all brains, exact same microscope set-up (including objective, zoom, laser power, gain) was used to acquire all pictures within the same experiment. All pictures were taken with a pinhole of 1 airy unit (AU). For representative images maximum intensity projections were made in FIJI (NIH) and images were equally adjusted for brightness and contrast.

#### Quantitative Analysis of FGF21 Fluorescent *In Situ* Hybridization and GFAP Immunohistochemistry {#sec6.4.23.8}

For quantification of *FGF21*-positive and GFAP-astrocytes expression, the total number of *FGF21* and GFAP co-expressing astrocytes as well as the total number of GFAP expressing astrocytes was quantified unilaterally in images from every fourth section from 8 control mice, 8 GLP-1R^ΔGFAP^ mice and 8 GLP-1R;FGF21^ΔGFAP^ mice using ImageJ analysis software (NIH) as previously reported ([@bib96], [@bib97]). The average number of *FGF21* and GFAP co-expressing astrocytes counted in 2 corresponding hemisections of the ARH from each animal was used for statistical comparison and the average percentage of FGF21 and GFAP co-expressing astrocytes in each genotype group was calculated. Analysis settings were kept the same throughout quantification of all pictures.

#### Fluorescent *In Situ* Hybridization of GLP1R Combined with Immunohistochemistry of GFAP {#sec6.4.23.9}

Mice were deeply anesthetized and perfused transcardially with 0.9% saline followed by 4% PFA. Brains were removed, postfixed overnight in 4% PFA and then transferred to 20% sucrose in 0.1 M PBS (pH 7.4) overnight. Perfused brains were frozen and afterward 30 μm thick sections were cut on a cryostat. Fluorescent *in situ* hybridization for the detection of the *GLP1R* was performed using RNAscope (ACD; Advanced Cell Diagnostics, Hayward, CA). The probe used to detect *GLP1R* was targeting the region 108 - 1203 of the *GLP1R* transcript (Acc. No: [NM_021332.2](ncbi-n:NM_021332.2){#intref0235}; ACD). Negative and positive control probes recognizing dihydrodipicolinate reductase, DapB (a bacterial transcript) and cyclophilin and PolR2A, respectively, were processed in parallel with the target probes to ensure tissue RNA integrity and optimal assay performance. Thereby a negative control section of the hypothalamus from every animal was run in parallel. All pretreatment reagents, detection kit and wash buffer were purchased from ACD. All incubation steps were performed at 40°C using a humidified chamber and a HybEz oven (ACD) unless indicated otherwise. On the day before the assay, sections were defrosted and briefly dipped in diethyl-pyrocarbonate (DEPC) treated Millipore water and dried at 60°C overnight. On the day of the assay, slides were steamed at 100°C in Target Retrieval (ACD) for 10 min, followed by two brief rinses in DEPC water. The slides were then quickly dehydrated in 100% ethanol and allowed to air dry overnight. The following day, sections were incubated with Protease Plus (ACD) for 25 min. The subsequent steps, i.e., hybridization of the probe, the amplification steps and detection of the probe, were performed according to the online protocol for RNAscope Enhancer Fluorescent Kit v2 (\#323100, ACD). In brief, the procedure included the following steps: The *GLP1R* probe (channel 1) was hybridized to the sections for 2 h, followed by 2x2 min washes in wash buffer (ACD), incubation with Amp1 for 30 min, two washes, Amp2 for 30 min, two washes and finally Amp3 for 15 min followed by two washes. Sections were then incubated in HRP-C1 solution for 15 min followed by two washes and then incubated in channel 1-probe associated TSA Plus Opal690 (1:750, \#NEL745E001KT, Perkin Elmer) for 30 min followed by two washes and a subsequent incubation in HRP blocker solution for 15 min followed by two washes. Sections were then subjected to GFAP staining via immunohistochemistry. Therefore, slides were blocked using 3% donkey serum (diluted in 0.25% Triton X, 0.1 M PBS) for 60 min. Following, slides were incubated with anti-GFAP antibody (\#7260, Abcam,1:1000, diluted in Signal Stain, Cell Signaling) for 16 h at 4°C. Slides were then washed 3 x with PBS for 10 min and incubated with the secondary antibody (donkey-anti-rabbit, Alexa 488 (\#A21206)), 1:500 diluted in 0.1 M PBS, 0.25% Triton X) for 60 min. After a final washing with 3 × 0.1 M PBS, 0.1% Triton X for 10 min, slides were mounted with DAPI-containing vectashield (Vector Laboratories). Images were acquired using a confocal Leica TCS SP-8-X microscope equipped with a 40x objective for acquisition of *GLP1R* and GFAP staining. To ensure similar imaging conditions for all pictures of all brains, exact same microscope set-up (including objective, zoom, laser power, gain) was used to acquire all pictures within the same experiment. All pictures were taken with a pinhole of 1 airy unit (AU). For representative images maximum intensity projections were made in FIJI (NIH) and images were equally adjusted for brightness and contrast.

Quantification and Statistical Analysis {#sec6.5}
---------------------------------------

All values were expressed as mean ± SEM except when stated otherwise. Statistical analyses were conducted using GraphPad PRISM (version 7.0) unless indicated otherwise. Statistical details of experiments can be found in the figure legends and the respective methods section. Unless otherwise specified in the figure legends, datasets with only two independent groups were analyzed for statistical significance using unpaired, two-tailed Student's t test or Mann-Whitney test. Datasets with more than two groups were analyzed using one-way ANOVA, followed by Bonferroni or Tukey post hoc test. Datasets with two independent factors were analyzed using two-way ANOVA, followed by Bonferroni post hoc test. All p values below or equal to 0.05 were considered significant. ^∗^ p ≤ 0.05, ^∗∗^ p ≤ 0.01, and ^∗∗∗^ p ≤ 0.001.
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